<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="iso-abbrev">Oxid Med Cell Longev</journal-id><journal-id journal-id-type="publisher-id">OMCL</journal-id><journal-title-group><journal-title>Oxidative Medicine and Cellular Longevity</journal-title></journal-title-group><issn pub-type="ppub">1942-0900</issn><issn pub-type="epub">1942-0994</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5933010</article-id><article-id pub-id-type="doi">10.1155/2018/4039753</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Antifibrogenic Influence of <italic>Mentha piperita</italic> L. Essential Oil against CCl<sub>4</sub>-Induced Liver Fibrosis in Rats</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0480-5127</contrib-id><name><surname>Ogaly</surname><given-names>Hanan A.</given-names></name><email>ohanan@kku.edu.sa</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eltablawy</surname><given-names>Nadia A.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Abd-Elsalam</surname><given-names>Reham M.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Chemistry, College of Sciences, King Khalid University, Abha, Saudi Arabia</aff><aff id="I2">
<sup>2</sup>Biochemistry Division, National Organization for Drug Control and Research (NODCAR), Giza, Egypt</aff><aff id="I3">
<sup>3</sup>Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt</aff><author-notes><fn fn-type="other"><p>Academic Editor: Sudipta Saha</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>19</day><month>4</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>4039753</elocation-id><history><date date-type="received"><day>11</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>10</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Hanan A. Ogaly et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Essential oils of some aromatic plants provide an effective nonmedicinal option to control liver fibrosis. <italic>Mentha piperita</italic> L. essential oil (MPEO) have been reported to possess protective effects against hepatotoxicity. However, its effect against liver fibrosis remains unknown. The present study investigated the antifibrogenic potential of MPEO and its underlying mechanisms. Forty male rats divided into 4 groups were used: group 1 served as normal control, group 2 (liver fibrosis) received CCl<sub>4</sub> (2.5&#x02009;mL/kg, IP, twice weekly) for 8 weeks, group 3 concurrently received CCl<sub>4</sub> plus MPEO (50&#x02009;mg/kg, IP, daily, from the 3rd week), and group 4 received MPEO only. MPOE significantly improved the liver injury markers, lipid peroxidation (LPO), antioxidant capacity, CYP2E1 gene expressionand liver histology. Furthermore, MPOE ameliorated liver fibrosis as evidenced by the reduced expression of desmin, <italic>&#x003b1;</italic>-smooth muscle actin (<italic>&#x003b1;</italic>-SMA), transforming growth factor-<italic>&#x003b2;</italic>1 (TGF-<italic>&#x003b2;</italic>1), and SMAD3 proteins. In addition, MPOE counteracted the p53 upregulation induced by CCl<sub>4</sub> at both mRNA and protein levels. In conclusion, MPOE could effectively attenuate hepatic fibrosis mainly through improving the redox status, suppressing p53 and subsequently modulating TGF-<italic>&#x003b2;</italic>1 and SMAD3 protein expression. These data promote the use of MPOE as a promising approach in antifibrotic therapy.</p></abstract><funding-group><award-group><funding-source>King Khalid University</funding-source><award-id>G.R.P-267-38</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Liver fibrosis and cirrhosis are the ultimate consequences of chronic hepatic injury induced by various etiological agents [<xref rid="B1" ref-type="bibr">1</xref>]. The mechanism of liver fibrosis has been extensively studied. However, effective antifibrotic therapies are lacking [<xref rid="B2" ref-type="bibr">2</xref>]. The pathogenesis of hepatic fibrosis is generally based on the activation of HSCs and excessive extracellular matrix (ECM) production [<xref rid="B2" ref-type="bibr">2</xref>]. Oxidative stress plays a central role in triggering these inflammatory and fibrotic responses [<xref rid="B3" ref-type="bibr">3</xref>]. Among the various signaling pathways involved in pathogenesis of liver fibrosis, TGF-<italic>&#x003b2;</italic>1/SMAD is considered the most significant signaling pathway [<xref rid="B4" ref-type="bibr">4</xref>]. Therefore, inhibiting TGF-<italic>&#x003b2;</italic>1 was found to be efficient in attenuating liver fibrosis [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. The tumor suppressor p53 is another important cell signal primarily stimulated in response to oxidative damage and oncogene activation [<xref rid="B7" ref-type="bibr">7</xref>]. Accumulating evidences suggested the involvement of p53 in the pathophysiology of various nontumoral fibrotic liver diseases in both human and animals [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. These data suggest that p53 regulation could serve as an important therapeutic target for fibrotic liver diseases.</p><p>Medicinal plants and their derivatives contain a wide variety of bioactive phytochemicals with a diverse pharmacological spectrum [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. Essential oils constituents including terpenes, terpenoids, phenylpropenes, and other degradation products have been reported to exhibit strong antioxidant and anti-inflammatory activities [<xref rid="B12" ref-type="bibr">12</xref>]. The effectiveness of some essential oils to alleviate the hepatotoxicity [<xref rid="B13" ref-type="bibr">13</xref>] and hepatic fibrosis [<xref rid="B14" ref-type="bibr">14</xref>] has been proven. <italic>Mentha piperita</italic> L. (peppermint) is one of the most popular and widely used herbs. Pharmacological investigations have demonstrated that <italic>M. piperita</italic> possesses analgesic, antifungal [<xref rid="B15" ref-type="bibr">15</xref>], antibacterial [<xref rid="B16" ref-type="bibr">16</xref>], antiparasitic, and immunomodulatory activities [<xref rid="B17" ref-type="bibr">17</xref>]. Moreover, the hepatoprotective effects of <italic>M. piperita</italic> leaves extract [<xref rid="B18" ref-type="bibr">18</xref>], oil [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>], or its active components menthol and menthone [<xref rid="B21" ref-type="bibr">21</xref>] have been reported. However, to the best of our knowledge, the effect against hepatic fibrosis has not been reported. Therefore, the present study aimed to investigate the effects of <italic>Mentha piperita</italic> L. essential oil (MPEO) against hepatic fibrosis and to elucidate the potential underlying molecular mechanisms.</p></sec><sec id="sec2"><title>2. Material and Methods</title><sec id="sec2.1"><title>2.1. MPOE Preparation and Characterization</title><p>
<italic>Mentha piperita</italic> L. leaves were purchased from Harraz Drug stores (Cairo, Egypt). A voucher specimen of the studied plant material was deposited at Biochemistry Department, National Organization for Drug Control and Research (NODCAR), Egypt. Essential oil was extracted and characterized for its chemical composition using gas-liquid chromatography coupled to mass spectrometry (GC-MS) as described by Ogaly et al. [<xref rid="B14" ref-type="bibr">14</xref>].</p></sec><sec id="sec2.2"><title>2.2. Experimental Design</title><p>Adult male rats (150&#x02013;170&#x02009;g) were obtained from the breeding unit of the Research Institute of Ophthalmology (Giza, Egypt). Rats were housed under constant temperature and 12&#x02009;h light/dark cycle with free access to water and standard chow diet. All animal procedures were performed according to the protocol approved by the Institutional Animal Care and Use Committee (IACUC), Cairo University (CU-II-F-1-18).</p><p>Forty rats were randomly divided into four groups. Group 1 (control) was given corn oil (2&#x02009;mL/kg, IP). Group 2 (fibrosis model) was given CCl<sub>4</sub> 1&#x02009;:&#x02009;4 mixture with corn oil (2.5&#x02009;mL/kg, IP) twice weekly for eight weeks. Rats in group 3 received CCl<sub>4</sub> for two weeks to establish liver injury and fibrosis and then treated with MPOE (50&#x02009;mg/kg, IP), daily from the 3rd to 8th week. Group 4 received MPOE (50&#x02009;mg/kg, IP) from the 3rd to 8th week. The selected dose for MPOE (50&#x02009;mg/kg) was previously reported to be hepatoprotective for rats [<xref rid="B20" ref-type="bibr">20</xref>].</p></sec><sec id="sec2.3"><title>2.3. Samples Collection</title><p>At the end of experiment, animals were anesthetized with ethyl ether. Blood samples (3-4&#x02009;mL) were collected by retro-orbital puncture, and serum was separated by centrifugation (4000&#x02009;rpm/10&#x02009;min). Afterward, all animals were sacrificed by cervical dislocation under ethyl ether anesthesia for humane reasons; the whole liver was immediately removed, rinsed in cold normal saline, and kept at &#x02212;20&#x000b0;C until further analyses. Liver homogenates (10%) were prepared in 0.1&#x02009;M ice-cold phosphate buffered saline (pH&#x02009;7.4) followed by centrifugation at 14,000&#x02009;&#x000d7;g, 15&#x02009;min at 4&#x000b0;C. The separated supernatants were kept at &#x02212;20&#x000b0;C. For histopathological examination, parts of liver were fixed in 10% neutral buffered formalin and underwent routine processing for paraffin embedding.</p></sec><sec id="sec2.4"><title>2.4. Biochemical Analyses</title><p>Serum samples were used to measure liver injury markers alanine aminotransferase (ALT) and aspartate aminotransferase (AST) according to the method of Reitman and Frankel [<xref rid="B22" ref-type="bibr">22</xref>]. Liver homogenates were used for measurement of nitric oxide (NO) [<xref rid="B23" ref-type="bibr">23</xref>], malondialdehyde (MDA) as a thiobarbituric acid reactive substance (TBARS) [<xref rid="B24" ref-type="bibr">24</xref>], superoxide dismutase (SOD) activity [<xref rid="B25" ref-type="bibr">25</xref>], catalase (CAT) activity [<xref rid="B26" ref-type="bibr">26</xref>], reduced glutathione (GSH) level [<xref rid="B27" ref-type="bibr">27</xref>], and total antioxidant capacity (TAC) using commercial kits (Biodiagnostic, Cairo, Egypt). Total protein content was measured according to the method of Bradford [<xref rid="B28" ref-type="bibr">28</xref>].</p></sec><sec id="sec2.5"><title>2.5. Histopathological Analyses</title><p>Seven liver samples were harvested from each experimental group and fixed in 10% neutral buffered formalin and then processed to obtain 4&#x02009;<italic>&#x003bc;</italic>m paraffin-embedded sections. The sections were stained with hematoxylin and eosin (H&#x00026;E) and Masson's trichrome (MT). MT staining was performed to assess collagen fibers distribution and to determine liver fibrosis %. A numerical scoring system [<xref rid="B29" ref-type="bibr">29</xref>] was performed to assess the grade of fibrosis, as follows: 0, no fibrosis (normal); 1, fibrous expansion of some portal areas; 2, fibrous expansion of most portal areas; 3, fibrous expansion of most portal areas with occasional portal-to-portal bridging; 4, fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central); 5, marked bridging (portal to central as well as central to central) with occasional nodules formation; and 6, cirrhosis.</p></sec><sec id="sec2.6"><title>2.6. Immunohistochemical Analyses</title><p>The immunohistochemical (IHC) analyses were done according to the methods of Ogaly et al. [<xref rid="B14" ref-type="bibr">14</xref>]. Briefly, tissue sections were deparaffinized and rehydrated. The antigen retrieval was performed by pretreating the tissue sections for 20&#x02009;min with citrate buffer pH 6 at microwave oven. Sections were incubated with rabbit polyclonal antibody to <italic>&#x003b1;</italic>-SMA diluted 1&#x02009;:&#x02009;200 (ab5694; Abcam, Cambridge, UK), rabbit polyclonal antidesmin antibody diluted 1&#x02009;:&#x02009;200 (ab15200; Abcam, Cambridge, UK), rabbit polyclonal anti-TGF-<italic>&#x003b2;</italic>1 antibody with concentration of 20&#x02009;<italic>&#x003bc;</italic>g/mL (ab92486; Abcam, Cambridge, UK), rabbit polyclonal anti-SMAD3 antibody diluted 1&#x02009;:&#x02009;100 (ab28379; Abcam, Cambridge, UK), and rabbit polyclonal anti-Tp53 antibody diluted 1&#x02009;:&#x02009;100 (ab131442; Abcam, Cambridge, UK) for two hours in a humidified chamber. The tissue sections were incubated with goat antirabbit IgG H&#x00026;L (HRP) (ab205718; Abcam, Cambridge, UK). Finally, the slides were incubated for 10&#x02009;min with 3,3&#x02032;-diaminobenzidine tetrahydrochloride (DAB; Sigma) as chromagen, counterstained with hematoxylin, and mounted with DPX. The image analyses of the stained sections were performed by Leica Qwin 500 Image Analyzer (Leica, Cambridge, England). In each group, seven sections were examined. The percentage of the immunopositive area (%) was calculated as mean of 10 fields/section.</p></sec><sec id="sec2.7"><title>2.7. Gene Expression Analyses</title><p>Total RNA isolated from liver tissues using RNeasy Mini Kit (Qiagen) was reverse transcribed and subjected to quantitative real-time RT-PCR as previously described [<xref rid="B14" ref-type="bibr">14</xref>]. mRNA expression levels of Tp53 and CYP2E1 genes were assessed using GAPDH gene as the reference gene. Briefly, cDNA was added to a Quantifast SYBR Green qPCR Master Mix (Qiagen) containing 30&#x02009;pg/mL of each primer (<xref ref-type="table" rid="tab1">Table 1</xref>). The thermal program included 40 cycles of denaturation at 95&#x000b0;C for 15&#x02009;s, annealing at 60&#x000b0;C for 15&#x02009;s, and extension at 72&#x000b0;C for 45&#x02009;s. The first denaturation was extended to 1&#x02009;min. Calculation of gene expression was done following Livak and Schmittgen [<xref rid="B30" ref-type="bibr">30</xref>].</p></sec><sec id="sec2.8"><title>2.8. Statistical Analysis</title><p>SPSS version 16.0 statistical package was used to analyze the data. All data were expressed as mean&#x02009;&#x000b1;&#x02009;standard error (SE). One-way analysis of variance (ANOVA) was used to assess the differences between groups. Difference was considered statistically significant at <italic>p</italic> &#x0003c; 0.05 by Duncan's multiple comparisons.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Chemical Composition of MPEO</title><p>Hydrodistilled MPEO was subjected to qualitative and quantitative analyses using gas chromatography coupled with mass spectrophotometry (GC-MS). Ten chemical constituents could be identified by elution on HP-5872 column (<xref ref-type="table" rid="tab2">Table 2</xref>). The major constituents of MPEO, in order of their percentage (<xref ref-type="fig" rid="fig1">Figure 1</xref>), were menthol (46.7%), <italic>p</italic>-menthone (18.3%), <sc>l</sc>-carvone (15.2%), pulegone (6.3%), <italic>iso</italic>-menthone (5.3%), and <sc>d</sc>-camphor (3.3%). Small amounts of 1,8-cineol, beta pinene, <italic>trans</italic>-caryophyllene, and limonene were also identified.</p></sec><sec id="sec3.2"><title>3.2. MPEO Improves Liver Functions in CCl<sub>4</sub>-Induced Liver Fibrosis</title><p>As shown in <xref ref-type="table" rid="tab3">Table 3</xref>, CCl<sub>4</sub>-intoxicated rats (group 2) showed a severe increase in liver marker enzymes, ALT and AST, to about 62- and 23-folds, respectively, compared to the control group. MPOE coadministration (group 3) exerted a significant reduction of ALT and AST levels to 76.8% and 60.4%, respectively, as compared to the CCl<sub>4</sub> group. There were no significant differences in liver enzymes between groups 1 and 4 (<xref ref-type="table" rid="tab3">Table 3</xref>).</p></sec><sec id="sec3.3"><title>3.3. MPEO Attenuates Oxidative Stress in CCl<sub>4</sub>-Induced Liver Fibrosis</title><p>CCl<sub>4</sub> caused a marked disruption of oxidant/antioxidant balance in liver as indicated by the statistically significant elevation in MDA and NO levels to 236% and 407% in group 2 as compared to the control group (<xref ref-type="table" rid="tab3">Table 3</xref>). Besides, there was a marked reduction in SOD and CAT antioxidant enzymes activities with a dramatic depletion in hepatic GSH content to 24.4%, 43.2%, and 23.4% of the control levels, respectively (<xref ref-type="table" rid="tab4">Table 4</xref>). In the same line, TAC of the liver of CCl<sub>4</sub>-intoxicated group showed a significant reduction to 39.7% (<xref ref-type="table" rid="tab4">Table 4</xref>). Administration of MPOE concurrently with CCl<sub>4</sub> for 6 weeks (group 3) showed a significant reduction of MDA and NO levels compared to those of group 2 (<xref ref-type="table" rid="tab3">Table 3</xref>). MPOE partially restored SOD and CAT activities and GSH level (<xref ref-type="table" rid="tab4">Table 4</xref>). Improvement of CCl<sub>4</sub>-induced oxidative stress by MPOE was confirmed by the significant elevation of TAC, reaching 74% of the normal control level (<xref ref-type="table" rid="tab4">Table 4</xref>). There were no significant differences in all measured oxidative stress markers or antioxidant parameters between groups 1 and 4 (Tables <xref ref-type="table" rid="tab3">3</xref> and <xref ref-type="table" rid="tab4">4</xref>).</p></sec><sec id="sec3.4"><title>3.4. MPEO Ameliorates Fibrotic Alterations in CCl<sub>4</sub>-Induced Liver Fibrosis</title><p>The histopathological examination of the normal and MPOE groups revealed normal histological hepatic architecture (Figures <xref ref-type="fig" rid="fig2">2(a)</xref> and <xref ref-type="fig" rid="fig2">2(d)</xref>). The fibrosis control group (group 2) showed marked fatty degeneration of the hepatocytes, hepatocellular necrosis with mononuclear inflammatory cell aggregation, and collagen fibers bridging (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). Group 3, receiving CCl<sub>4</sub>&#x02009;+&#x02009;MPOE, showed marked attenuation of the previously described histopathological lesions compared to the fibrotic control group (<xref ref-type="fig" rid="fig2">Figure 2(c)</xref>). With MT staining, the liver of the control and MPEO groups showed normal distribution of collagen fibers (Figures <xref ref-type="fig" rid="fig3">3(a)</xref> and <xref ref-type="fig" rid="fig3">3(d)</xref>). The fibrotic control group showed severe bridging fibrosis with marked collagen deposition in the liver extending from portal to portal, portal to central, and central to central and formation of pseudolobules (<xref ref-type="fig" rid="fig3">Figure 3(b)</xref>). In group 3 (CCl<sub>4</sub>&#x02009;+&#x02009;MPEO), the collagen deposition was markedly reduced, and the collagenous septa became thinner than those of the fibrotic control group (<xref ref-type="fig" rid="fig3">Figure 3(c)</xref>). The histopathological grading of liver fibrosis and the morphometric analysis of liver fibrosis % in different groups are shown in <xref ref-type="table" rid="tab5">Table 5</xref> and <xref ref-type="fig" rid="fig3">Figure 3(e)</xref>, respectively, group 1 and 4 showed no significant difference in the liver fibrosis grading or fibrosis % (<xref ref-type="fig" rid="fig3">Figure 3(e)</xref> and <xref ref-type="table" rid="tab5">Table 5</xref>). Group 3 (CCl<sub>4</sub>&#x02009;+&#x02009;MPEO) showed significant reduction of the grading of liver fibrosis and fibrosis % compared to the fibrosis control group 2 as shown in <xref ref-type="fig" rid="fig3">Figure 3(e)</xref> and <xref ref-type="table" rid="tab5">Table 5</xref>.</p></sec><sec id="sec3.5"><title>3.5. MPEO Regulates Profibrogenic Protein Expression in CCl<sub>4</sub>-Induced Fibrosis</title><p>
<italic>&#x003b1;</italic>-SMA and desmin immunoreactivity appeared to be cytoplasmic and stained brown in colour. <italic>&#x003b1;</italic>-SMA expression was seen in smooth muscle cells of the blood vessels in the normal control and the MPOE control (Figures <xref ref-type="fig" rid="fig4">4(a)</xref> and <xref ref-type="fig" rid="fig4">4(d)</xref>). In the liver fibrosis control group, <italic>&#x003b1;</italic>-SMA staining located in the myofibroblast cells along collagenous septa bridging portal areas and central areas and desmin immunostaining was observed in perisinusoidal cells and interstitial myofibroblasts. <italic>&#x003b1;</italic>-SMA and desmin protein expression were significantly elevated in liver fibrosis control group than in the normal control (Figures <xref ref-type="fig" rid="fig4">4</xref> and <xref ref-type="fig" rid="fig5">5</xref>). Group 3 (MPOE-treated) showed a significant reduction of <italic>&#x003b1;</italic>-SMA and desmin protein expression compared to the liver fibrosis control group (Figures <xref ref-type="fig" rid="fig4">4</xref> and <xref ref-type="fig" rid="fig5">5</xref>). TGF-<italic>&#x003b2;</italic>1 was a cytoplasmic immunostaining, and it was observed in periductal cells in the portal tract of the normal control and MPOE control groups (Figures <xref ref-type="fig" rid="fig6">6(a)</xref> and <xref ref-type="fig" rid="fig6">6(d)</xref>). SMAD3 expression was nuclear and cytoplasmic immunostaining. The fibrotic control group showed TGF-<italic>&#x003b2;</italic>1 immunoreactivity in the periductal cells in the portal tract, in perisinusoidal cells, around the blood vessels, in sinusoidal lining cells, in inflammatory cells, and in the network around the necrotic hepatocytes; and a small amount was observed in necrotic hepatocytes. TGF-<italic>&#x003b2;</italic>1 and SMAD3 protein expression were significantly increased in the liver fibrosis control group than in the normal control (Figures <xref ref-type="fig" rid="fig6">6</xref> and <xref ref-type="fig" rid="fig7">7</xref>). Group 3 (MPOE-treated) showed a sustained reduction of TGF-<italic>&#x003b2;</italic>1 and SMAD3 protein expression compared to the liver fibrosis control group (Figures <xref ref-type="fig" rid="fig6">6</xref> and <xref ref-type="fig" rid="fig7">7</xref>, resp.). No significant difference was recorded between the normal control and MPOE control groups.</p></sec><sec id="sec3.6"><title>3.6. MPEO Downregulates p53 Expression in CCl<sub>4</sub>-Induced Fibrosis</title><p>Tp53 gene expression level showed a significant elevation in the liver fibrosis control (group 2). Tp53 mRNA level reached to about 16-folds of the control level. This CCl<sub>4</sub>-induced overexpression of Tp53 was markedly suppressed in MPOE-treated rats to about 2-fold as compared to that in the control (<xref ref-type="fig" rid="fig8">Figure 8(a)</xref>). At the protein level, p53 immunoreactivity was significantly increased in the liver fibrosis control. Group 3 treated with CCl<sub>4</sub>&#x02009;+&#x02009;MPOE showed significantly decreased p53 immunoreactivity (<xref ref-type="fig" rid="fig9">Figure 9(c)</xref>). <xref ref-type="fig" rid="fig9"> Figure 9(e)</xref> summarizes the IHC analysis of p53 protein expression in the different groups. Nonsignificant differences in p53 mRNA and protein levels were detected between groups 1 and 4 (Figures <xref ref-type="fig" rid="fig8">8(a)</xref> and <xref ref-type="fig" rid="fig9">9</xref>), respectively.</p></sec><sec id="sec3.7"><title>3.7. MPEO Restored CYP2E1 Expression in CCl<sub>4</sub>-Induced Liver Fibrosis</title><p>Quantitative RT-PCR analysis showed a significant decrease in CYP2E1 mRNA in the liver fibrosis control group to 27% of that of the control group. MPOE-treated rats in group 3 showed marked increase in mRNA level to +2.32-folds of the normal level (<xref ref-type="fig" rid="fig8">Figure 8(b)</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Fibrogenesis is a multicellular wound healing process that occurs as a frequent consequence of many chronic liver injuries [<xref rid="B1" ref-type="bibr">1</xref>]. Regardless of its etiology, hepatic fibrosis is generally characterized by oxidative tissue damage, inflammatory cells infiltration, HSCs activation, and excessive collagen deposition [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. Accumulating clinical and experimental evidences have shown that the halting of the fibrogenic process may allow the reversal of liver fibrosis. Indeed, resolution of liver fibrosis or even cirrhosis may occur upon eradication of the causative insult [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>]. Oxidative stress has been proposed as a conjoint pathological mechanism in the initiation and progression of fibrosis [<xref rid="B3" ref-type="bibr">3</xref>]. Thereby, inhibition of ROS-mediated fibrogenesis might yield great potential therapeutic benefits. In this context, attention is progressively shifting towards herbal products and their antioxidant constituents [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. <italic>M. piperita</italic> has been known for its great multipharmaceutical benefits [<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>]. The active phytocompounds of MPEO contribute to many of its profound therapeutic actions. Although the hepatoprotective effect of MPOE was previously demonstrated [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>], its antifibrogenic influence against hepatic fibrosis has not been investigated yet. The present study aimed to evaluate the potential of MPOE to ameliorate CCl<sub>4</sub>-induced hepatic fibrosis in rats and to elucidate some aspects of its underlying molecular mechanisms.</p><p>MPEO was reported to have a wide range of components, including menthol, menthone, menthofuran, and methyl acetate, and other pharmacologically active compounds such as flavonoids, tannins, and caffeic acid [<xref rid="B37" ref-type="bibr">37</xref>]. In the current study, the chemical profile of MPEO, as presented in <xref ref-type="table" rid="tab2">Table 2</xref>, is characterized by the dominant presence of the oxygenated monoterpenes menthol (46.7%) and menthone (18.3%). A high percentage of carvone (15%) was observed compared to that of the composition previously reported by Sun et al. [<xref rid="B38" ref-type="bibr">38</xref>]. Different chemotypes of <italic>M. piperita</italic> were reported in other countries in which the major constituent in MPEO is linalool as in <italic>M. piperita</italic> collected from Brazil [<xref rid="B39" ref-type="bibr">39</xref>] or limonene as in <italic>M. piperita</italic> collected from India [<xref rid="B40" ref-type="bibr">40</xref>]. This diversity in the chemical composition may be attributed to geographical and soil condition, biosynthetic factors, and collection time [<xref rid="B38" ref-type="bibr">38</xref>]. However, the composition of MPEO presented in the current study still maintains a certain level of chemosimilarity with some previously reported MPEO compositions [<xref rid="B38" ref-type="bibr">38</xref>]. Mentha species are known for their ability to exhibit strong antioxidant and radical scavenging activities owing to the presence of valuable secondary metabolites in the essential oil and phenolic substances [<xref rid="B41" ref-type="bibr">41</xref>]. Previous studies showed that the radical scavenging activity of essential oil of <italic>M. piperita</italic> species is attributed to the presence of menthone and menthol, with the presence of the hydroxyl radical (<sup>&#x02022;</sup>OH). The vast majority of these antioxidants (<xref ref-type="fig" rid="fig1">Figure 1</xref>) have the ability to trap the free radicals and interrupt the chain reaction due to the presence of at least one aromatic ring in their structures [<xref rid="B42" ref-type="bibr">42</xref>].</p><p>CCl<sub>4</sub>-induced fibrosis has been extensively used as an <italic>in vivo</italic> model for the study of liver damage [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>]. CCl<sub>4</sub> toxicity represents a multifactorial process involving its detoxification by CYP450 into the highly reactive CCl<sub>4</sub>-derived free radicals, covalent binding to macromolecules, stimulation of inflammatory cytokines, oxidative damage with subsequent necrosis of hepatocytes, and activation of HSCs [<xref rid="B44" ref-type="bibr">44</xref>].</p><p>Fibrogenesis is mediated by a complex interplay of signaling pathways. Of particular note, TGF-<italic>&#x003b2;</italic>1/SMAD is one of the core mechanisms of fibrogenesis [<xref rid="B45" ref-type="bibr">45</xref>]. Recently, much information has emerged concerning the central role of TGF-<italic>&#x003b2;</italic>1 as the principal driver of excessive scarring and tissue fibrosis. TGF-<italic>&#x003b2;</italic>1, in HSCs, acts by stimulating collagen I expression and inhibiting ECM degradation [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B46" ref-type="bibr">46</xref>]. Excessive TGF-<italic>&#x003b2;</italic>1 release by necrotic hepatocytes is considered as one of the first signals to adjacent quiescent HSCs to be activated by transdifferentiation into myofibroblasts-like cells [<xref rid="B47" ref-type="bibr">47</xref>]. Upon activation, TGF-<italic>&#x003b2;</italic>1 binds to its cell-surface receptor complexes and initiates an intracellular signaling cascade resulting in phosphorylation of SMAD2 and SMAD3. Subsequently, the activated SMAD2 and SMAD3 form stable oligomer complexes with SMAD4. These complexes actively shuttle into the nucleus to regulate the transcription of target genes [<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>]. It has been demonstrated that SMAD3 is a key element in TGF-<italic>&#x003b2;</italic>1&#x02013;induced fibrosis [<xref rid="B50" ref-type="bibr">50</xref>]. A number of fibrogenic genes (e.g., collagens) and markers (e.g., <italic>&#x003b1;</italic>-SMA) are SMAD3-dependent as SMAD3 directly binds to the DNA regulatory sequences of these target genes [<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>]. Moreover, SMAD3 inhibits matrix metalloprotease 1 activity in fibroblasts and activates tissue inhibitor of metalloproteases and thus inhibits ECM degradation [<xref rid="B53" ref-type="bibr">53</xref>]. Considering this major role of TGF-<italic>&#x003b2;</italic>1 signaling in the pathobiology of liver fibrosis, TGF-<italic>&#x003b2;</italic>1 or its downstream mediators may provide important targets for the new therapeutic strategies of liver fibrosis [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>In the present study, eight weeks of CCl<sub>4</sub> administration was sufficient to induce severe hepatotoxic changes detected by the considerably elevated activities of serum ALT and AST markers (<xref ref-type="table" rid="tab3">Table 3</xref>). Increased release of these cytosolic enzymes in the serum reflects hepatocyte damage and leakage and provides important diagnostic biomarkers for hepatic diseases [<xref rid="B54" ref-type="bibr">54</xref>]. Moreover, high AST and ALT levels are associated with an increased risk of fibrosis progression [<xref rid="B55" ref-type="bibr">55</xref>]. MPEO administration reversed the elevated levels of ALT and AST compared to those of the CCl<sub>4</sub> group. These findings are consistent with those of previous studies [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>].</p><p>LPO is thought to be the initiation step of CCl<sub>4</sub> hepatotoxicity [<xref rid="B56" ref-type="bibr">56</xref>]. Lipid hydroperoxides are unstable and so degrade rapidly into a variety of secondary metabolites such as MDA, 4-hydroxynonenal (4-HNE), and other conjugated dienes [<xref rid="B57" ref-type="bibr">57</xref>]. MDA serves as a main biomarker to assess the level of lipoperoxidative tissue damage [<xref rid="B58" ref-type="bibr">58</xref>]. In accordance with previous studies [<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>], a significant increase in liver MDA content was observed in the CCl<sub>4</sub> group, suggesting an enhanced LPO (<xref ref-type="table" rid="tab3">Table 3</xref>).</p><p>Furthermore, CCl<sub>4</sub>-intoxicated rats showed a significant increase in the liver NO (<xref ref-type="table" rid="tab3">Table 3</xref>). This elevated NO indicates the stimulation of inflammatory cells and release of inflammatory cytokines [<xref rid="B61" ref-type="bibr">61</xref>]. NO participates in the induction of fibrosis through its reaction with superoxide anions forming highly reactive peroxynitrite radicals, which induce HSCs activation and accelerate the progression of liver fibrosis [<xref rid="B56" ref-type="bibr">56</xref>]. The obtained results closely agreed with those mentioned by Sagor et al. [<xref rid="B62" ref-type="bibr">62</xref>] and Abdel Salam et al. [<xref rid="B63" ref-type="bibr">63</xref>], who suggested the correlation between the hepatic NO content and the degree of liver fibrosis.</p><p>On the other hand, a significant decline in the liver antioxidant capacity was detected in the CCl<sub>4</sub> group evidenced by the decreased SOD and CAT activities and the depletion in GSH content (<xref ref-type="table" rid="tab4">Table 4</xref>). This disturbance in the prooxidants/antioxidants balance was further verified by the low TAC (<xref ref-type="table" rid="tab4">Table 4</xref>).</p><p>Histopathological analysis of liver sections provided an initial evidence of CCl<sub>4</sub>-induced liver hepatocellular damage and fibrosis (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="table" rid="tab5">Table 5</xref>). Degenerative changes including fatty degeneration, congestion, and cytoplasmic vacuolization were observed in the liver fibrosis control group (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). These findings were in agreement with those obtained by Ogaly et al. [<xref rid="B14" ref-type="bibr">14</xref>] and Yacout et al. [<xref rid="B64" ref-type="bibr">64</xref>]. Additionally, MT staining revealed clear fibrotic bridging in the liver sections of group 2 (<xref ref-type="fig" rid="fig3">Figure 3(b)</xref>).</p><p>Immunohistochemical analysis of desmin, a hallmark of both quiescent and activated HSCs, revealed a significant elevation in desmin-immunopositive cells in the livers of CCl<sub>4</sub>-injured group 2 (<xref ref-type="fig" rid="fig5">Figure 5(b)</xref>). In accordance with Fujii et al. [<xref rid="B65" ref-type="bibr">65</xref>], this finding implicates increased numbers of HSCs in the livers of CCl<sub>4</sub>-treated animals, as expression of desmin together with the stellate-shaped morphology is the main characteristic feature of HSCs [<xref rid="B66" ref-type="bibr">66</xref>].</p><p>Another important evidence for the activation of HSCs and progression of fibrosis was the significantly increased number of <italic>&#x003b1;</italic>-SMA-immunopositive cells in the CCl<sub>4</sub> fibrosis group (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref>), as compared to the control group (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>). <italic>&#x003b1;</italic>-SMA is a reliable hallmark for HSCs activation into the myofibroblastic phenotype and considered as an important myogenic marker that plays a significant role in collagen I deposition by activated HSCs [<xref rid="B67" ref-type="bibr">67</xref>]. These obtained findings, in accordance with Rockey et al. [<xref rid="B68" ref-type="bibr">68</xref>], indicate that CCl<sub>4</sub> stimulated HSCs activation and transdifferentiation. Moreover, it was found that SMAD3 increases <italic>&#x003b1;</italic>-SMA production and stimulates its organization into stress fibers [<xref rid="B69" ref-type="bibr">69</xref>].</p><p>In the current study, the livers of group 2 showed an augmented expression of TGF-<italic>&#x003b2;</italic>1 and SMAD3 proteins as detected by the increased immunoreactivity compared to those of the control group (Figures <xref ref-type="fig" rid="fig6">6</xref> and <xref ref-type="fig" rid="fig7">7</xref>). Similar findings were previously reported in rats [<xref rid="B44" ref-type="bibr">44</xref>].</p><p>MPOE at the investigated dose (50&#x02009;mg/kg) significantly improved the liver indices, antioxidant profile, and histological picture of liver tissue. MPOE significantly reduced serum ALT and AST, indicating a preserved liver integrity and improved function (<xref ref-type="table" rid="tab3">Table 3</xref>). MPOE treatment markedly increased the liver antioxidant capacity by restraining the LPO byproduct (MDA) and simultaneously enhancing the activities of SOD, catalase, and regeneration of GSH (<xref ref-type="table" rid="tab4">Table 4</xref>). Our data come in line with previous studies that reported the hepatoprotective effect of <italic>M. piperita</italic> [<xref rid="B18" ref-type="bibr">18</xref>] or its oil [<xref rid="B19" ref-type="bibr">19</xref>]. It was suggested that several active components of Mentha have antioxidant and antiperoxidant activities that provoke the capacity of endogenous antioxidant systems and protect against toxic hepatic damages [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B70" ref-type="bibr">70</xref>].</p><p>Coadministration of MPOE with CCl<sub>4</sub> significantly improved the liver histopathology (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and reduced the fibrotic changes (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="table" rid="tab5">Table 5</xref>). Furthermore, the MPOE-treated group showed a marked reduction in both <italic>&#x003b1;</italic>-SMA- and desmin-immunopositive cells (Figures <xref ref-type="fig" rid="fig4">4(c)</xref> and <xref ref-type="fig" rid="fig5">5(c)</xref>). These data reflect the efficacy of MPOE to reduce the hepatocellular toxic effects of CCl<sub>4</sub> and to suppress HSCs activation and proliferation as well.</p><p>In the same context, MPOE-treated group 3 showed marked reductions in TGF-<italic>&#x003b2;</italic>1 and SMAD3 proteins expression (Figures <xref ref-type="fig" rid="fig6">6(c)</xref> and <xref ref-type="fig" rid="fig7">7(c)</xref>) compared to the CCl<sub>4</sub> fibrosis group (Figures <xref ref-type="fig" rid="fig6">6(b)</xref> and <xref ref-type="fig" rid="fig7">7(b)</xref>). According to Kanzler et al. [<xref rid="B47" ref-type="bibr">47</xref>] and Chen et al. [<xref rid="B71" ref-type="bibr">71</xref>], the observed suppression in TGF-<italic>&#x003b2;</italic>1 protein expression and the subsequent downregulation of SMAD3 in the livers of group 3 could explain the observed reduction of <italic>&#x003b1;</italic>-SMA-positive cells (<xref ref-type="fig" rid="fig4">Figure 4(c)</xref>), collagen deposition (<xref ref-type="fig" rid="fig3">Figure 3(c)</xref>), and fibrosis % (<xref ref-type="fig" rid="fig3">Figure 3(e)</xref>) and the reduced fibrosis scores (<xref ref-type="table" rid="tab5">Table 5</xref>) in this group in comparison with the liver fibrosis control group. These findings support the antifibrogenic potential of MPOE against CCl<sub>4</sub>-induced liver fibrosis.</p><p>p53 is a tumor-suppressor protein that regulates the transcription of a plethora of target proteins involved in the cell cycle, differentiation, and apoptosis [<xref rid="B72" ref-type="bibr">72</xref>]. In normal redox state, p53 expression and degradation are tightly regulated by a variety of proteins to maintain a low level of p53 [<xref rid="B73" ref-type="bibr">73</xref>]. Different stress signals including ROS, hypoxia, and oncogene activation induce p53 that becomes transcriptionally active, leading to cell cycle arrest, DNA repair, and apoptosis [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. It was reported that hepatocyte p53 activation resulted in spontaneous liver fibrosis and induced hepatocyte apoptosis, in addition to upregulation of connective tissue growth factor (CTGF) [<xref rid="B74" ref-type="bibr">74</xref>]. <italic>In vitro</italic> study showed that p53 induces CTGF in hepatocytes that occur via regulation of microRNA [<xref rid="B75" ref-type="bibr">75</xref>].</p><p>Recent studies highlighted the possible involvement of p53 in fibrogenesis as a profibrotic mediator [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B74" ref-type="bibr">74</xref>]. p53 has been implicated as an inducer of several profibrotic effectors such as TGF-<italic>&#x003b2;</italic>1, CTGF, <italic>&#x003b1;</italic>-SMA, and fibronectin [<xref rid="B76" ref-type="bibr">76</xref>]. During the fibrogenic process, a crosstalk between p53 and TGF-<italic>&#x003b2;</italic>1 has been suggested to stimulate transcription of the fibrogenic target genes [<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>]. Under oxidative stress, excessive ROS induces various transcription factors such as p53, activator protein-1 (AP-1), and NF-<italic>&#x003ba;</italic>B by altering the DNA binding sites or by oxidizing the cysteine residues of such proteins resulting in conformational change of their tertiary structure with subsequent protein degradation activation or inhibition. Activated p53 plays a crucial role in inducing apoptosis to prevent the propagation of DNA damage [<xref rid="B72" ref-type="bibr">72</xref>].</p><p>Few reports on the role of p53 and TGF-<italic>&#x003b2;</italic>1 and their interplay in the mechanism of fibrogenesis have arisen [<xref rid="B75" ref-type="bibr">75</xref>&#x02013;<xref rid="B78" ref-type="bibr">78</xref>]. This encouraged our team to study the possible role of p53 and TGF-<italic>&#x003b2;</italic>1 in MPEO antifibrogenic mechanism. In the current investigation, Tp53 mRNA level showed a significant increase in response to CCl<sub>4</sub> fibrosis (<xref ref-type="fig" rid="fig8">Figure 8(a)</xref>). Consequently, a considerable level of p53 protein was detected in the livers of the fibrosis group (<xref ref-type="fig" rid="fig9">Figure 9</xref>). These findings agreed with those of previous studies that reported that p53 expression increases following the onset of liver injury [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. In the MPOE-treated group, both Tp53 mRNA (<xref ref-type="fig" rid="fig8">Figure 8(a)</xref>) and p53 protein expression (<xref ref-type="fig" rid="fig9">Figure 9(c)</xref>) were significantly suppressed. This p53 downregulation might have contributed to the reduced hepatic fibrosis in this group.</p><p>Pharmacological p53 inhibitors have been proposed as a therapeutic application to alleviate tissue fibrosis [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>Analysis of CYP2E1 gene expression aimed to evaluate for the detoxifying capacity of the liver. CCl<sub>4</sub> intoxication resulted in a significant suppression in CYP2E1 mRNA (<xref ref-type="fig" rid="fig8">Figure 8(b)</xref>). This specific CYP2E1 downregulation in CCl<sub>4</sub> hepatic fibrosis was previously reported [<xref rid="B18" ref-type="bibr">18</xref>] and may have contributed to a direct attack of CYP2E1 transcript by the reactive CCl<sub>4</sub> metabolites leading to its degradation. Besides, the inflammatory response associated with fibrosis could exert a suppressive effect on CYP2E1 expression [<xref rid="B79" ref-type="bibr">79</xref>]. Interestingly, MPOE treatment counteracted this CYP2E1 downregulation (<xref ref-type="fig" rid="fig8">Figure 8</xref>). This preservation of CYP2E1 expression could be one of the MPOE hepatoprotective and antifibrogenic actions [<xref rid="B80" ref-type="bibr">80</xref>]. These findings are consistent with those of previous studies [<xref rid="B62" ref-type="bibr">62</xref>] that reported the ability of peppermint to modulate both phase I and phase II liver drug-metabolizing enzymes. Besides, eugenol, an active component of MPOE (<xref ref-type="table" rid="tab2">Table 2</xref>), has been previously shown to induce detoxification enzymes [<xref rid="B18" ref-type="bibr">18</xref>].</p></sec><sec id="sec5"><title>5. Conclusion</title><p>MPEO significantly ameliorates the severity of CCl<sub>4</sub>-induced liver fibrosis through improving the oxidative status and restoring hepatic CYP2E1 expression. These MPEO actions could be mediated by inhibiting TGF-<italic>&#x003b2;</italic>1/SMAD signaling proteins and downregulation of p53 at both gene and protein levels. These data suggest that MPEO might be an effective antifibrogenic agent in the prevention of liver fibrosis progression. MPEO could help in developing a promising approach against oxidation-caused liver fibrosis.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through General Research Project under grant number (G.R.P-267-38).</p></ack><sec><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>S. L.</given-names></name></person-group><article-title>Mechanisms of hepatic fibrogenesis</article-title><source><italic>Gastroenterology</italic></source><year>2008</year><volume>134</volume><issue>6</issue><fpage>1655</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.03.003</pub-id><pub-id pub-id-type="other">2-s2.0-42949163491</pub-id><?supplied-pmid 18471545?><pub-id pub-id-type="pmid">18471545</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Potent effects of dioscin against liver fibrosis</article-title><source><italic>Scientific Reports</italic></source><year>2015</year><volume>5</volume><issue>1, article 9713</issue><pub-id pub-id-type="doi">10.1038/srep09713</pub-id><pub-id pub-id-type="other">2-s2.0-84927779859</pub-id><?supplied-pmid 25853178?><pub-id pub-id-type="pmid">25853178</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Tan</surname><given-names>H.-Y.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The role of oxidative stress and antioxidants in liver diseases</article-title><source><italic>International Journal of Molecular Sciences</italic></source><year>2015</year><volume>16</volume><issue>11</issue><fpage>26087</fpage><lpage>26124</lpage><pub-id pub-id-type="doi">10.3390/ijms161125942</pub-id><pub-id pub-id-type="other">2-s2.0-84946595368</pub-id><?supplied-pmid 26540040?><pub-id pub-id-type="pmid">26540040</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>N. C.</given-names></name><name><surname>Sheppard</surname><given-names>D.</given-names></name></person-group><article-title>Integrin-mediated regulation of TGF<italic>&#x003b2;</italic> in fibrosis</article-title><source><italic>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</italic></source><year>2013</year><volume>1832</volume><issue>7</issue><fpage>891</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2012.10.005</pub-id><pub-id pub-id-type="other">2-s2.0-84877025203</pub-id><?supplied-pmid 23046811?><pub-id pub-id-type="pmid">23046811</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbloom</surname><given-names>J.</given-names></name><name><surname>Mendoza</surname><given-names>F. A.</given-names></name><name><surname>Jimenez</surname><given-names>S. A.</given-names></name></person-group><article-title>Strategies for anti-fibrotic therapies</article-title><source><italic>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</italic></source><year>2013</year><volume>1832</volume><issue>7</issue><fpage>1088</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2012.12.007</pub-id><pub-id pub-id-type="other">2-s2.0-84877035619</pub-id><?supplied-pmid 23266403?><pub-id pub-id-type="pmid">23266403</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verrecchia</surname><given-names>F.</given-names></name><name><surname>Mauviel</surname><given-names>A.</given-names></name></person-group><article-title>Transforming growth factor-<italic>&#x003b2;</italic> and fibrosis</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2007</year><volume>13</volume><issue>22</issue><fpage>3056</fpage><lpage>3062</lpage><pub-id pub-id-type="doi">10.3748/wjg.v13.i22.3056</pub-id><?supplied-pmid 17589920?><pub-id pub-id-type="pmid">17589920</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname><given-names>K. H.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group><article-title>Live or let die: the cell&#x02019;s response to p53</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2002</year><volume>2</volume><issue>8</issue><fpage>594</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1038/nrc864</pub-id><pub-id pub-id-type="other">2-s2.0-0036674617</pub-id><?supplied-pmid 12154352?><pub-id pub-id-type="pmid">12154352</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>T.</given-names></name><name><surname>Takehara</surname><given-names>T.</given-names></name><name><surname>Hikita</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2011</year><volume>121</volume><issue>8</issue><fpage>3343</fpage><lpage>3356</lpage><pub-id pub-id-type="doi">10.1172/JCI44957</pub-id><pub-id pub-id-type="other">2-s2.0-79961010787</pub-id><?supplied-pmid 21747166?><pub-id pub-id-type="pmid">21747166</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attallah</surname><given-names>A. M.</given-names></name><name><surname>Shiha</surname><given-names>G. E.</given-names></name><name><surname>Ismail</surname><given-names>H.</given-names></name><name><surname>Mansy</surname><given-names>S. E.</given-names></name><name><surname>El-Sherbiny</surname><given-names>R.</given-names></name><name><surname>El-Dosoky</surname><given-names>I.</given-names></name></person-group><article-title>Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection</article-title><source><italic>Clinical Biochemistry</italic></source><year>2009</year><volume>42</volume><issue>6</issue><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2008.11.004</pub-id><pub-id pub-id-type="other">2-s2.0-62149130461</pub-id><?supplied-pmid 19063876?><pub-id pub-id-type="pmid">19063876</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>J. P.</given-names></name><name><surname>Evan Prince</surname><given-names>S.</given-names></name></person-group><article-title>Natural remedies for non-steroidal anti-inflammatory drug-induced toxicity</article-title><source><italic>Journal of Applied Toxicology</italic></source><year>2017</year><volume>37</volume><issue>1</issue><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1002/jat.3391</pub-id><pub-id pub-id-type="other">2-s2.0-84992504670</pub-id><?supplied-pmid 27652576?><pub-id pub-id-type="pmid">27652576</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>F.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Yuen</surname><given-names>M. F.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>V. T.</given-names></name></person-group><article-title>Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials</article-title><source><italic>Chinese Medicine</italic></source><year>2012</year><volume>7</volume><issue>1</issue><fpage>p. 5</fpage><pub-id pub-id-type="doi">10.1186/1749-8546-7-5</pub-id><pub-id pub-id-type="other">2-s2.0-84857467292</pub-id><?supplied-pmid 22376935?><pub-id pub-id-type="pmid">22376935</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misharina</surname><given-names>T. A.</given-names></name><name><surname>Terenina</surname><given-names>M. B.</given-names></name><name><surname>Krikunova</surname><given-names>N. I.</given-names></name></person-group><article-title>Antioxidant properties of essential oils</article-title><source><italic>Prikladnaia Biokhimiia i Mikrobiologiia</italic></source><year>2009</year><volume>45</volume><issue>6</issue><fpage>710</fpage><lpage>716</lpage><?supplied-pmid 20067158?><pub-id pub-id-type="pmid">20067158</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheweita</surname><given-names>S. A.</given-names></name><name><surname>El-Hosseiny</surname><given-names>L. S.</given-names></name><name><surname>Nashashibi</surname><given-names>M. A.</given-names></name></person-group><article-title>Protective effects of essential oils as natural antioxidants against hepatotoxicity induced by cyclophosphamide in mice</article-title><source><italic>PLoS One</italic></source><year>2016</year><volume>11</volume><issue>11, article e0165667</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0165667</pub-id><pub-id pub-id-type="other">2-s2.0-84994000003</pub-id><?supplied-pmid 27802299?><pub-id pub-id-type="pmid">27802299</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogaly</surname><given-names>H. A.</given-names></name><name><surname>Eltablawy</surname><given-names>N. A.</given-names></name><name><surname>El-Behairy</surname><given-names>A. M.</given-names></name><name><surname>El-Hindi</surname><given-names>H.</given-names></name><name><surname>Abd-Elsalam</surname><given-names>R. M.</given-names></name></person-group><article-title>Hepatocyte growth factor mediates the antifibrogenic action of <italic>Ocimum bacilicum</italic> essential oil against CCl<sub>4</sub>-induced liver fibrosis in rats</article-title><source><italic>Molecules</italic></source><year>2015</year><volume>20</volume><issue>8</issue><fpage>13518</fpage><lpage>13535</lpage><pub-id pub-id-type="doi">10.3390/molecules200813518</pub-id><pub-id pub-id-type="other">2-s2.0-84941236894</pub-id><?supplied-pmid 26213907?><pub-id pub-id-type="pmid">26213907</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saharkhiz</surname><given-names>M. J.</given-names></name><name><surname>Motamedi</surname><given-names>M.</given-names></name><name><surname>Zomorodian</surname><given-names>K.</given-names></name><name><surname>Pakshir</surname><given-names>K.</given-names></name><name><surname>Miri</surname><given-names>R.</given-names></name><name><surname>Hemyari</surname><given-names>K.</given-names></name></person-group><article-title>Chemical composition, antifungal and antibiofilm activities of the essential oil of <italic>Mentha piperita</italic> L</article-title><source><italic>ISRN Pharmaceutics</italic></source><year>2012</year><volume>2012</volume><fpage>6</fpage><pub-id pub-id-type="publisher-id">718645</pub-id><pub-id pub-id-type="doi">10.5402/2012/718645</pub-id><?supplied-pmid 23304561?><pub-id pub-id-type="pmid">23304561</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goudjil</surname><given-names>M. B.</given-names></name><name><surname>Ladjel</surname><given-names>S.</given-names></name><name><surname>Bencheikh</surname><given-names>S. E.</given-names></name><name><surname>Zighmi</surname><given-names>S.</given-names></name><name><surname>Hamada</surname><given-names>D.</given-names></name></person-group><article-title>Chemical composition, antibacterial and antioxidant activities of the essential oil extracted from the <italic>Mentha piperita</italic> of Southern Algeria</article-title><source><italic>Research Journal of Phytochemistry</italic></source><year>2015</year><volume>9</volume><issue>2</issue><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3923/rjphyto.2015.79.87</pub-id><pub-id pub-id-type="other">2-s2.0-84945922311</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejani</surname><given-names>N. N.</given-names></name><name><surname>Souza</surname><given-names>L. C.</given-names></name><name><surname>Oliveira</surname><given-names>S. R. P.</given-names></name><etal/></person-group><article-title>Immunological and parasitological parameters in <italic>Schistosoma mansoni</italic>-infected mice treated with crude extract from the leaves of <italic>Mentha</italic> &#x000d7; <italic>piperita</italic> L</article-title><source><italic>Immunobiology</italic></source><year>2014</year><volume>219</volume><issue>8</issue><fpage>627</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2014.03.015</pub-id><pub-id pub-id-type="other">2-s2.0-84902075350</pub-id><?supplied-pmid 24767421?><pub-id pub-id-type="pmid">24767421</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>M. K.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name></person-group><article-title>Protective effect of <italic>Mentha piperita</italic> against arsenic-induced toxicity in liver of Swiss albino mice</article-title><source><italic>Basic &#x00026; Clinical Pharmacology &#x00026; Toxicology</italic></source><year>2007</year><volume>100</volume><issue>4</issue><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2006.00030.x</pub-id><pub-id pub-id-type="other">2-s2.0-33947258994</pub-id><?supplied-pmid 17371529?><pub-id pub-id-type="pmid">17371529</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>A. F.</given-names></name><name><surname>Elkatry</surname><given-names>H. O.</given-names></name><name><surname>El Mehairy</surname><given-names>H. F.</given-names></name></person-group><article-title>Protective effect of peppermint and parsley leaves oils against hepatotoxicity on experimental rats</article-title><source><italic>Annals of Agricultural Sciences</italic></source><year>2015</year><volume>60</volume><issue>2</issue><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.aoas.2015.11.004</pub-id><pub-id pub-id-type="other">2-s2.0-84995565800</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marjani</surname><given-names>A.</given-names></name><name><surname>Rahmati</surname><given-names>R.</given-names></name><name><surname>Mansourian</surname><given-names>A. R.</given-names></name><name><surname>Veghary</surname><given-names>G.</given-names></name></person-group><article-title>Effect of peppermint oil on serum lipid peroxidation and hepatic enzymes after immobility stress in mice</article-title><source><italic>The Open Biochemistry Journal</italic></source><year>2012</year><volume>6</volume><issue>1</issue><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.2174/1874091X01206010051</pub-id><pub-id pub-id-type="other">2-s2.0-84863792855</pub-id><?supplied-pmid 22654997?><pub-id pub-id-type="pmid">22654997</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaia</surname><given-names>M. G.</given-names></name><name><surname>di Orlando Cagnazzo</surname><given-names>T.</given-names></name><name><surname>Feitosa</surname><given-names>K. A.</given-names></name><etal/></person-group><article-title>Anti-inflammatory properties of menthol and menthone in <italic>Schistosoma mansoni</italic> infection</article-title><source><italic>Frontiers in Pharmacology</italic></source><year>2016</year><volume>7</volume><fpage>p. 170</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00170</pub-id><pub-id pub-id-type="other">2-s2.0-84977651140</pub-id><?supplied-pmid 27378927?><pub-id pub-id-type="pmid">27378927</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitman</surname><given-names>S.</given-names></name><name><surname>Frankel</surname><given-names>S.</given-names></name></person-group><article-title>A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases</article-title><source><italic>American Journal of Clinical Pathology</italic></source><year>1957</year><volume>28</volume><issue>1</issue><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/ajcp/28.1.56</pub-id><?supplied-pmid 13458125?><pub-id pub-id-type="pmid">13458125</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>K. M.</given-names></name><name><surname>Espey</surname><given-names>M. G.</given-names></name><name><surname>Wink</surname><given-names>D. A.</given-names></name></person-group><article-title>A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite</article-title><source><italic>Nitric Oxide</italic></source><year>2001</year><volume>5</volume><issue>1</issue><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1006/niox.2000.0319</pub-id><pub-id pub-id-type="other">2-s2.0-0035709008</pub-id><?supplied-pmid 11178938?><pub-id pub-id-type="pmid">11178938</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Placer</surname><given-names>Z. A.</given-names></name><name><surname>Cushman</surname><given-names>L. L.</given-names></name><name><surname>Johnson</surname><given-names>B. C.</given-names></name></person-group><article-title>Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems</article-title><source><italic>Analytical Biochemistry</italic></source><year>1966</year><volume>16</volume><issue>2</issue><fpage>359</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(66)90167-9</pub-id><pub-id pub-id-type="other">2-s2.0-0013937181</pub-id><?supplied-pmid 6007581?><pub-id pub-id-type="pmid">6007581</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>A.</given-names></name><name><surname>Chatterjee</surname><given-names>&#x00399;. B.</given-names></name></person-group><article-title>Assay of superoxide dismutase activity in animal tissues</article-title><source><italic>Journal of Biosciences</italic></source><year>1988</year><volume>13</volume><issue>3</issue><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/BF02712155</pub-id><pub-id pub-id-type="other">2-s2.0-51649151855</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>A. K.</given-names></name></person-group><article-title>Colorimetric assay of catalase</article-title><source><italic>Analytical Biochemistry</italic></source><year>1972</year><volume>47</volume><issue>2</issue><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(72)90132-7</pub-id><pub-id pub-id-type="other">2-s2.0-0015353270</pub-id><?supplied-pmid 4556490?><pub-id pub-id-type="pmid">4556490</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>E.</given-names></name><name><surname>Duron</surname><given-names>O.</given-names></name><name><surname>Kelly</surname><given-names>B. M.</given-names></name></person-group><article-title>Improved method for the determination of blood glutathione</article-title><source><italic>The Journal of Laboratory and Clinical Medicine</italic></source><year>1963</year><volume>61</volume><fpage>882</fpage><lpage>888</lpage><?supplied-pmid 13967893?><pub-id pub-id-type="pmid">13967893</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradford</surname><given-names>M. M.</given-names></name></person-group><article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding</article-title><source><italic>Analytical Biochemistry</italic></source><year>1976</year><volume>72</volume><issue>1-2</issue><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(76)90527-3</pub-id><pub-id pub-id-type="other">2-s2.0-0017184389</pub-id><pub-id pub-id-type="pmid">942051</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishak</surname><given-names>K.</given-names></name><name><surname>Baptista</surname><given-names>A.</given-names></name><name><surname>Bianchi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Histological grading and staging of chronic hepatitis</article-title><source><italic>Journal of Hepatology</italic></source><year>1995</year><volume>22</volume><issue>6</issue><fpage>696</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/0168-8278(95)80226-6</pub-id><pub-id pub-id-type="other">2-s2.0-0029039362</pub-id><?supplied-pmid 7560864?><pub-id pub-id-type="pmid">7560864</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>K. J.</given-names></name><name><surname>Schmittgen</surname><given-names>T. D.</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>&#x02212;&#x00394;&#x00394;<italic>C</italic></sup>T method</article-title><source><italic>Methods</italic></source><year>2001</year><volume>25</volume><issue>4</issue><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="other">2-s2.0-0035710746</pub-id><?supplied-pmid 11846609?><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devi</surname><given-names>S. L.</given-names></name><name><surname>Anuradha</surname><given-names>C. V.</given-names></name></person-group><article-title>Oxidative and nitrosative stress in experimental rat liver fibrosis: protective effect of taurine</article-title><source><italic>Environmental Toxicology and Pharmacology</italic></source><year>2010</year><volume>29</volume><issue>2</issue><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.etap.2009.11.005</pub-id><pub-id pub-id-type="other">2-s2.0-77951620307</pub-id><?supplied-pmid 21787590?><pub-id pub-id-type="pmid">21787590</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Hong</surname><given-names>M.</given-names></name><name><surname>Tan</surname><given-names>H. Y.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name></person-group><article-title>Insights into the role and interdependence of oxidative stress and inflammation in liver diseases</article-title><source><italic>Oxidative Medicine and Cellular Longevity</italic></source><year>2016</year><volume>2016</volume><fpage>21</fpage><pub-id pub-id-type="publisher-id">4234061</pub-id><pub-id pub-id-type="doi">10.1155/2016/4234061</pub-id><pub-id pub-id-type="other">2-s2.0-85008873207</pub-id><?supplied-pmid 28070230?><pub-id pub-id-type="pmid">28070230</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trautwein</surname><given-names>C.</given-names></name><name><surname>Friedman</surname><given-names>S. L.</given-names></name><name><surname>Schuppan</surname><given-names>D.</given-names></name><name><surname>Pinzani</surname><given-names>M.</given-names></name></person-group><article-title>Hepatic fibrosis: concept to treatment</article-title><source><italic>Journal of Hepatology</italic></source><year>2015</year><volume>62</volume><issue>1</issue><supplement>Supplement 1</supplement><fpage>S15</fpage><lpage>S24</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.02.039</pub-id><pub-id pub-id-type="other">2-s2.0-84930654452</pub-id><pub-id pub-id-type="pmid">25920084</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>P.</given-names></name><name><surname>Iredale</surname><given-names>J. P.</given-names></name><name><surname>Fallowfield</surname><given-names>J. A.</given-names></name></person-group><article-title>Resolution of liver fibrosis: basic mechanisms and clinical relevance</article-title><source><italic>Seminars in Liver Disease</italic></source><year>2015</year><volume>35</volume><issue>2</issue><fpage>119</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1550057</pub-id><pub-id pub-id-type="other">2-s2.0-84929309326</pub-id><?supplied-pmid 25974898?><pub-id pub-id-type="pmid">25974898</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharafi</surname><given-names>S. M.</given-names></name><name><surname>Rasooli</surname><given-names>I.</given-names></name><name><surname>Owlia</surname><given-names>P.</given-names></name><name><surname>Taghizadeh</surname><given-names>M.</given-names></name><name><surname>Astaneh</surname><given-names>S. D. A.</given-names></name></person-group><article-title>Protective effects of bioactive phytochemicals from <italic>Mentha piperita</italic> with multiple health potentials</article-title><source><italic>Pharmacognosy Magazine</italic></source><year>2010</year><volume>6</volume><issue>23</issue><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.4103/0973-1296.66926</pub-id><pub-id pub-id-type="other">2-s2.0-78049378052</pub-id><?supplied-pmid 20931070?><pub-id pub-id-type="pmid">20931070</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>D. L.</given-names></name><name><surname>Blumberg</surname><given-names>J. B.</given-names></name></person-group><article-title>A review of the bioactivity and potential health benefits of peppermint tea (<italic>Mentha piperita</italic> L.)</article-title><source><italic>Phytotherapy Research</italic></source><year>2006</year><volume>20</volume><issue>8</issue><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1002/ptr.1936</pub-id><pub-id pub-id-type="other">2-s2.0-33747248900</pub-id><?supplied-pmid 16767798?><pub-id pub-id-type="pmid">16767798</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Shushni</surname><given-names>M. A. M.</given-names></name><name><surname>Belkheir</surname><given-names>A.</given-names></name></person-group><article-title>Antibacterial and antioxidant activities of <italic>Mentha piperita</italic> L</article-title><source><italic>Arabian Journal of Chemistry</italic></source><year>2011</year><volume>8</volume><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2011.01.019</pub-id><pub-id pub-id-type="other">2-s2.0-84927967477</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name></person-group><article-title>Chemical composition and antiinflammatory, cytotoxic and antioxidant activities of essential oil from leaves of <italic>Mentha piperita</italic> grown in China</article-title><source><italic>PLoS One</italic></source><year>2014</year><volume>9</volume><issue>12, article e114767</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0114767</pub-id><pub-id pub-id-type="other">2-s2.0-84916886394</pub-id><?supplied-pmid 25493616?><pub-id pub-id-type="pmid">25493616</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva Ramos</surname><given-names>R.</given-names></name><name><surname>Rodrigues</surname><given-names>A. B. L.</given-names></name><name><surname>Farias</surname><given-names>A. L. F.</given-names></name><etal/></person-group><article-title>Chemical composition and <italic>in vitro</italic> antioxidant, cytotoxic, antimicrobial, and larvicidal activities of the essential oil of <italic>Mentha piperita</italic> L. (Lamiaceae)</article-title><source><italic>The Scientific World Journal</italic></source><year>2017</year><volume>2017</volume><fpage>8</fpage><pub-id pub-id-type="publisher-id">4927214</pub-id><pub-id pub-id-type="doi">10.1155/2017/4927214</pub-id><pub-id pub-id-type="other">2-s2.0-85010409203</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>A. K.</given-names></name><name><surname>Malik</surname><given-names>A.</given-names></name></person-group><article-title>Antimicrobial potential and chemical composition of <italic>Mentha piperita</italic> oil in liquid and vapour phase against food spoiling microorganisms</article-title><source><italic>Food Control</italic></source><year>2011</year><volume>22</volume><issue>11</issue><fpage>1707</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1016/j.foodcont.2011.04.002</pub-id><pub-id pub-id-type="other">2-s2.0-79957874177</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>N.</given-names></name><name><surname>Fazal</surname><given-names>H.</given-names></name><name><surname>Ahmad</surname><given-names>I.</given-names></name><name><surname>Abbasi</surname><given-names>B. H.</given-names></name></person-group><article-title>Free radical scavenging (DPPH) potential in nine <italic>Mentha</italic> species</article-title><source><italic>Toxicology and Industrial Health</italic></source><year>2012</year><volume>28</volume><issue>1</issue><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1177/0748233711407238</pub-id><pub-id pub-id-type="other">2-s2.0-84856455709</pub-id><?supplied-pmid 21646282?><pub-id pub-id-type="pmid">21646282</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brewer</surname><given-names>M. S.</given-names></name></person-group><article-title>Natural antioxidants: sources, compounds, mechanisms of action, and potential applications</article-title><source><italic>Comprehensive Reviews in Food Science and Food Safety</italic></source><year>2011</year><volume>10</volume><issue>4</issue><fpage>221</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/j.1541-4337.2011.00156.x</pub-id><pub-id pub-id-type="other">2-s2.0-79958798487</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>L.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Involvement of TGF-<italic>&#x003b2;</italic>1/Smad3 signaling in carbon tetrachloride-induced acute liver injury in mice</article-title><source><italic>PLoS One</italic></source><year>2016</year><volume>11</volume><issue>5, article e0156090</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0156090</pub-id><pub-id pub-id-type="other">2-s2.0-84971220796</pub-id><?supplied-pmid 27224286?><pub-id pub-id-type="pmid">27224286</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Moneim</surname><given-names>A. M.</given-names></name><name><surname>Al-Kahtani</surname><given-names>M. A.</given-names></name><name><surname>El-Kersh</surname><given-names>M. A.</given-names></name><name><surname>Al-Omair</surname><given-names>M. A.</given-names></name></person-group><article-title>Free radical-scavenging, anti-inflammatory/anti-fibrotic and hepatoprotective actions of taurine and silymarin against CCl<sub>4</sub> induced rat liver damage</article-title><source><italic>PLoS One</italic></source><year>2015</year><volume>10</volume><issue>12, article e0144509</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0144509</pub-id><pub-id pub-id-type="other">2-s2.0-84970938311</pub-id><?supplied-pmid 26659465?><pub-id pub-id-type="pmid">26659465</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>W. R.</given-names></name><name><surname>Yang</surname><given-names>C. Q.</given-names></name><name><surname>Shi</surname><given-names>Q.</given-names></name></person-group><article-title>Transforming growth factor-<italic>&#x003b2;</italic>1 induced epithelial-mesenchymal transition in hepatic fibrosis</article-title><source><italic>Hepato-Gastroenterology</italic></source><year>2012</year><volume>59</volume><issue>118</issue><fpage>1960</fpage><lpage>1963</lpage><pub-id pub-id-type="doi">10.5754/hge11750</pub-id><pub-id pub-id-type="other">2-s2.0-84865678756</pub-id><?supplied-pmid 22369740?><pub-id pub-id-type="pmid">22369740</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>Y.</given-names></name><name><surname>Okazaki</surname><given-names>I.</given-names></name></person-group><article-title>Emerging insights into transforming growth factor <italic>&#x003b2;</italic> Smad signal in hepatic fibrogenesis</article-title><source><italic>Gut</italic></source><year>2007</year><volume>56</volume><issue>2</issue><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1136/gut.2005.088690</pub-id><pub-id pub-id-type="other">2-s2.0-33846951514</pub-id><?supplied-pmid 17303605?><pub-id pub-id-type="pmid">17303605</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanzler</surname><given-names>S.</given-names></name><name><surname>Lohse</surname><given-names>A. W.</given-names></name><name><surname>Keil</surname><given-names>A.</given-names></name><etal/></person-group><article-title>TGF-<italic>&#x003b2;</italic>1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis</article-title><source><italic>American Journal of Physiology-Gastrointestinal and Liver Physiology</italic></source><year>1999</year><volume>276</volume><issue>4, Part 1</issue><fpage>G1059</fpage><lpage>G1068</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.1999.276.4.G1059</pub-id><?supplied-pmid 10198351?><pub-id pub-id-type="pmid">10198351</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>X.-M.</given-names></name><name><surname>Chung</surname><given-names>A. C. K.</given-names></name><name><surname>Lan</surname><given-names>H. Y.</given-names></name></person-group><article-title>Role of the TGF-<italic>&#x003b2;</italic>/BMP-7/Smad pathways in renal diseases</article-title><source><italic>Clinical Science</italic></source><year>2013</year><volume>124</volume><issue>4</issue><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1042/CS20120252</pub-id><pub-id pub-id-type="other">2-s2.0-84872104961</pub-id><?supplied-pmid 23126427?><pub-id pub-id-type="pmid">23126427</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>van Dam</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name></person-group><article-title>Regulation of TGF-<italic>&#x003b2;</italic> superfamily signaling by SMAD mono-ubiquitination</article-title><source><italic>Cell</italic></source><year>2014</year><volume>3</volume><issue>4</issue><fpage>981</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.3390/cells3040981</pub-id><?supplied-pmid 25317929?><pub-id pub-id-type="pmid">25317929</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Q. Y.</given-names></name><name><surname>Xu</surname><given-names>B. L.</given-names></name><name><surname>Wang</surname><given-names>J. Y.</given-names></name><name><surname>Liu</surname><given-names>H. C.</given-names></name><name><surname>Zhang</surname><given-names>S. C.</given-names></name><name><surname>Tu</surname><given-names>C. T.</given-names></name></person-group><article-title>Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats</article-title><source><italic>BMC Complementary &#x00026; Alternative Medicine</italic></source><year>2012</year><volume>12</volume><issue>1</issue><fpage>p. 156</fpage><pub-id pub-id-type="doi">10.1186/1472-6882-12-156</pub-id><pub-id pub-id-type="other">2-s2.0-84866146218</pub-id><?supplied-pmid 22978413?><pub-id pub-id-type="pmid">22978413</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latella</surname><given-names>G.</given-names></name><name><surname>Vetuschi</surname><given-names>A.</given-names></name><name><surname>Sferra</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice</article-title><source><italic>Liver International</italic></source><year>2009</year><volume>29</volume><issue>7</issue><fpage>997</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2009.02011.x</pub-id><pub-id pub-id-type="other">2-s2.0-67650501166</pub-id><?supplied-pmid 19422482?><pub-id pub-id-type="pmid">19422482</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masszi</surname><given-names>A.</given-names></name><name><surname>Kapus</surname><given-names>A.</given-names></name></person-group><article-title>Smaddening complexity: the role of Smad3 in epithelial-myofibroblast transition</article-title><source><italic>Cells, Tissues, Organs</italic></source><year>2011</year><volume>193</volume><issue>1-2</issue><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1159/000320180</pub-id><pub-id pub-id-type="other">2-s2.0-78650511931</pub-id><?supplied-pmid 21051861?><pub-id pub-id-type="pmid">21051861</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Muragaki</surname><given-names>Y.</given-names></name><name><surname>Saika</surname><given-names>S.</given-names></name><name><surname>Roberts</surname><given-names>A. B.</given-names></name><name><surname>Ooshima</surname><given-names>A.</given-names></name></person-group><article-title>Targeted disruption of TGF-<italic>&#x003b2;</italic>1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>2003</year><volume>112</volume><issue>10</issue><fpage>1486</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1172/JCI200319270</pub-id><pub-id pub-id-type="other">2-s2.0-0346727324</pub-id><?supplied-pmid 14617750?><pub-id pub-id-type="pmid">14617750</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinot-Peignoux</surname><given-names>M.</given-names></name><name><surname>Boyer</surname><given-names>N.</given-names></name><name><surname>Cazals-Hatem</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA</article-title><source><italic>Hepatology</italic></source><year>2001</year><volume>34</volume><issue>5</issue><fpage>1000</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1053/jhep.2001.28458</pub-id><pub-id pub-id-type="other">2-s2.0-0034761962</pub-id><?supplied-pmid 11679971?><pub-id pub-id-type="pmid">11679971</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuda</surname><given-names>M.</given-names></name><name><surname>D'Souza</surname><given-names>R.</given-names></name><name><surname>Upadhya</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Hepatoprotective and antioxidant activity of aqueous extract of <italic>Hybanthus enneaspermus</italic> against CCl<sub>4</sub>-induced liver injury in rats</article-title><source><italic>Experimental and Toxicologic Pathology</italic></source><year>2012</year><volume>64</volume><issue>7-8</issue><fpage>855</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1016/j.etp.2011.03.006</pub-id><pub-id pub-id-type="other">2-s2.0-84867668142</pub-id><?supplied-pmid 21478003?><pub-id pub-id-type="pmid">21478003</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>T. M.</given-names></name><name><surname>Fung</surname><given-names>M. L.</given-names></name><name><surname>Liong</surname><given-names>E. C.</given-names></name><name><surname>Lau</surname><given-names>T. Y.</given-names></name><name><surname>Nanji</surname><given-names>A. A.</given-names></name><name><surname>Tipoe</surname><given-names>G. L.</given-names></name></person-group><article-title>Role of nitric oxide in the regulation of fibrogenic factors in experimental liver fibrosis in mice</article-title><source><italic>Histology and Histopathology</italic></source><year>2011</year><volume>26</volume><issue>2</issue><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.14670/HH-26.201</pub-id><?supplied-pmid 21154234?><pub-id pub-id-type="pmid">21154234</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundaresan</surname><given-names>S.</given-names></name><name><surname>Subramanian</surname><given-names>P.</given-names></name></person-group><article-title>
<italic>S</italic>-Allylcysteine inhibits circulatory lipid peroxidation and promotes antioxidants in N-nitrosodiethylamine-induced carcinogenesis</article-title><source><italic>Polish Journal of Pharmacology</italic></source><year>2003</year><volume>55</volume><issue>1</issue><fpage>37</fpage><lpage>42</lpage><?supplied-pmid 12856824?><pub-id pub-id-type="pmid">12856824</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M. R.</given-names></name><name><surname>Ahmed</surname><given-names>D.</given-names></name></person-group><article-title>Protective effects of <italic>Digera muricata</italic> (L.) Mart. on testis against oxidative stress of carbon tetrachloride in rat</article-title><source><italic>Food and Chemical Toxicology</italic></source><year>2009</year><volume>47</volume><issue>6</issue><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2009.03.020</pub-id><pub-id pub-id-type="other">2-s2.0-67349150731</pub-id><?supplied-pmid 19327381?><pub-id pub-id-type="pmid">19327381</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaffari</surname><given-names>H.</given-names></name><name><surname>Venkataramana</surname><given-names>M.</given-names></name><name><surname>Nayaka</surname><given-names>S. C.</given-names></name><etal/></person-group><article-title>Hepatoprotective action of <italic>Orthosiphon diffusus</italic> (Benth.) methanol active fraction through antioxidant mechanisms: an <italic>in vivo</italic> and <italic>in vitro</italic> evaluation</article-title><source><italic>Journal of Ethnopharmacology</italic></source><year>2013</year><volume>149</volume><issue>3</issue><fpage>737</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2013.07.034</pub-id><pub-id pub-id-type="other">2-s2.0-84884411271</pub-id><?supplied-pmid 23933497?><pub-id pub-id-type="pmid">23933497</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>H.</given-names></name><name><surname>Hosseinzadeh</surname><given-names>S.</given-names></name><name><surname>Akbartabar Touri</surname><given-names>M.</given-names></name><name><surname>Ghavamzadeh</surname><given-names>M.</given-names></name><name><surname>Jafari Barmak</surname><given-names>M.</given-names></name></person-group><article-title>Hepatoprotective effect of <italic>Rosa canina</italic> fruit extract against carbon tetrachloride induced hepatotoxicity in rat</article-title><source><italic>Avicenna Journal of Phytomedicine</italic></source><year>2016</year><volume>6</volume><issue>2</issue><fpage>181</fpage><lpage>188</lpage><?supplied-pmid 27222831?><pub-id pub-id-type="pmid">27222831</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname><given-names>S.</given-names></name><name><surname>Karim</surname><given-names>R.</given-names></name><name><surname>Kitano</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Role of oxidative DNA damage caused by carbon tetrachloride-induced liver injury&#x02014;enhancement of MeIQ-induced glutathione <italic>S</italic>-transferase placental form-positive foci in rats</article-title><source><italic>Cancer Letters</italic></source><year>2002</year><volume>179</volume><issue>1</issue><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(01)00855-2</pub-id><pub-id pub-id-type="other">2-s2.0-0037042176</pub-id><?supplied-pmid 11880177?><pub-id pub-id-type="pmid">11880177</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagor</surname><given-names>A. T.</given-names></name><name><surname>Chowdhury</surname><given-names>M. R. H.</given-names></name><name><surname>Tabassum</surname><given-names>N.</given-names></name><name><surname>Hossain</surname><given-names>H.</given-names></name><name><surname>Rahman</surname><given-names>M. M.</given-names></name><name><surname>Alam</surname><given-names>M. A.</given-names></name></person-group><article-title>Supplementation of fresh ucche (<italic>Momordica charantia</italic> L. var. <italic>muricata</italic> Willd) prevented oxidative stress, fibrosis and hepatic damage in CCl<sub>4</sub> treated rats</article-title><source><italic>BMC Complementary &#x00026; Alternative Medicine</italic></source><year>2015</year><volume>15</volume><issue>1</issue><fpage>p. 115</fpage><pub-id pub-id-type="doi">10.1186/s12906-015-0636-1</pub-id><pub-id pub-id-type="other">2-s2.0-84964695336</pub-id><?supplied-pmid 25884170?><pub-id pub-id-type="pmid">25884170</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel Salam</surname><given-names>O. M.</given-names></name><name><surname>Sleem</surname><given-names>A. A.</given-names></name><name><surname>Shafee</surname><given-names>N.</given-names></name></person-group><article-title>Effect of trazodone and nefazodone on hepatic injury induced by carbon tetrachloride</article-title><source><italic>Drug Discoveries &#x00026; Therapeutics</italic></source><year>2010</year><volume>4</volume><issue>4</issue><fpage>285</fpage><lpage>297</lpage><?supplied-pmid 22491211?><pub-id pub-id-type="pmid">22491211</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yacout</surname><given-names>G. A.</given-names></name><name><surname>Elguindy</surname><given-names>N. M.</given-names></name><name><surname>El Azab</surname><given-names>E. F.</given-names></name></person-group><article-title>Hepatoprotective effect of basil (<italic>Ocimum basilicum</italic> L.) on CCl<sub>4</sub>-induced liver fibrosis in rats</article-title><source><italic>African Journal of Biotechnology</italic></source><year>2012</year><volume>11</volume><issue>90</issue><fpage>15702</fpage><lpage>15711</lpage><pub-id pub-id-type="doi">10.5897/ajb12.2048</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>T.</given-names></name><name><surname>Fuchs</surname><given-names>B. C.</given-names></name><name><surname>Yamada</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mouse model of carbon tetrachloride induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor</article-title><source><italic>BMC Gastroenterology</italic></source><year>2010</year><volume>10</volume><issue>1</issue><fpage>p. 79</fpage><pub-id pub-id-type="doi">10.1186/1471-230X-10-79</pub-id><pub-id pub-id-type="other">2-s2.0-77954324574</pub-id><?supplied-pmid 20618941?><pub-id pub-id-type="pmid">20618941</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kordes</surname><given-names>C.</given-names></name><name><surname>Sawitza</surname><given-names>I.</given-names></name><name><surname>M&#x000fc;ller-Marbach</surname><given-names>A.</given-names></name><etal/></person-group><article-title>CD133<sup>+</sup> hepatic stellate cells are progenitor cells</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2007</year><volume>352</volume><issue>2</issue><fpage>410</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.11.029</pub-id><pub-id pub-id-type="other">2-s2.0-33751539470</pub-id><?supplied-pmid 17118341?><pub-id pub-id-type="pmid">17118341</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotersztajn</surname><given-names>S.</given-names></name><name><surname>Julien</surname><given-names>B.</given-names></name><name><surname>Teixeira-Clerc</surname><given-names>F.</given-names></name><name><surname>Grenard</surname><given-names>P.</given-names></name><name><surname>Mallat</surname><given-names>A.</given-names></name></person-group><article-title>Hepatic fibrosis: molecular mechanisms and drug targets</article-title><source><italic>Annual Review of Pharmacology and Toxicology</italic></source><year>2005</year><volume>45</volume><issue>1</issue><fpage>605</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.095906</pub-id><pub-id pub-id-type="other">2-s2.0-13844306623</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockey</surname><given-names>D. C.</given-names></name><name><surname>Weymouth</surname><given-names>N.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name></person-group><article-title>Smooth muscle <italic>&#x003b1;</italic> actin (<italic>Acta2</italic>) and myofibroblast function during hepatic wound healing</article-title><source><italic>PLoS One</italic></source><year>2013</year><volume>8</volume><issue>10, article e77166</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0077166</pub-id><?supplied-pmid 24204762?><pub-id pub-id-type="pmid">24204762</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>TGF-<italic>&#x003b2;</italic>/SMAD pathway and its regulation in hepatic fibrosis</article-title><source><italic>Journal of Histochemistry &#x00026; Cytochemistry</italic></source><year>2016</year><volume>64</volume><issue>3</issue><fpage>157</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1369/0022155415627681</pub-id><pub-id pub-id-type="other">2-s2.0-84959374130</pub-id><?supplied-pmid 26747705?><pub-id pub-id-type="pmid">26747705</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaravelu</surname><given-names>P.</given-names></name><name><surname>Subramaniyam</surname><given-names>S.</given-names></name><name><surname>Dakshinamoorthy</surname><given-names>D. P.</given-names></name><name><surname>Devaraj</surname><given-names>N. S.</given-names></name></person-group><article-title>The antioxidant effect of eugenol on CCl<sub>4</sub>-induced erythrocyte damage in rats</article-title><source><italic>The Journal of Nutritional Biochemistry</italic></source><year>1996</year><volume>7</volume><issue>1</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0955-2863(95)00162-X</pub-id><pub-id pub-id-type="other">2-s2.0-0030044991</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H. B.</given-names></name><name><surname>Rud</surname><given-names>J. G.</given-names></name><name><surname>Lin</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name></person-group><article-title>Nuclear targeting of transforming growth factor-<italic>&#x003b2;</italic>-activated Smad complexes</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>22</issue><fpage>21329</fpage><lpage>21336</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500362200</pub-id><pub-id pub-id-type="other">2-s2.0-20444430827</pub-id><?supplied-pmid 15799969?><pub-id pub-id-type="pmid">15799969</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname><given-names>K. H.</given-names></name><name><surname>Prives</surname><given-names>C.</given-names></name></person-group><article-title>Blinded by the light: the growing complexity of p53</article-title><source><italic>Cell</italic></source><year>2009</year><volume>137</volume><issue>3</issue><fpage>413</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.037</pub-id><pub-id pub-id-type="other">2-s2.0-65349103899</pub-id><?supplied-pmid 19410540?><pub-id pub-id-type="pmid">19410540</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse</surname><given-names>J. P.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name></person-group><article-title>Modes of p53 regulation</article-title><source><italic>Cell</italic></source><year>2009</year><volume>137</volume><issue>4</issue><fpage>609</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.050</pub-id><pub-id pub-id-type="other">2-s2.0-65549120715</pub-id><?supplied-pmid 19450511?><pub-id pub-id-type="pmid">19450511</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.-F.</given-names></name><name><surname>Ji</surname><given-names>F.-J.</given-names></name><name><surname>Zang</surname><given-names>H.-L.</given-names></name><name><surname>Cao</surname><given-names>H.</given-names></name></person-group><article-title>Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis <italic>via</italic> inducing apoptosis in hepatocytes but not in HSCs</article-title><source><italic>PLoS One</italic></source><year>2016</year><volume>11</volume><issue>7, article e0158657</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0158657</pub-id><pub-id pub-id-type="other">2-s2.0-84978636812</pub-id><?supplied-pmid 27387128?><pub-id pub-id-type="pmid">27387128</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollutri</surname><given-names>D.</given-names></name><name><surname>Gramantieri</surname><given-names>L.</given-names></name><name><surname>Bolondi</surname><given-names>L.</given-names></name><name><surname>Fornari</surname><given-names>F.</given-names></name></person-group><article-title>TP53/microRNA interplay in hepatocellular carcinoma</article-title><source><italic>International Journal of Molecular Sciences</italic></source><year>2016</year><volume>17</volume><issue>12, article 2029</issue><pub-id pub-id-type="doi">10.3390/ijms17122029</pub-id><pub-id pub-id-type="other">2-s2.0-85004098312</pub-id><?supplied-pmid 27918441?><pub-id pub-id-type="pmid">27918441</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samarakoon</surname><given-names>R.</given-names></name><name><surname>Dobberfuhl</surname><given-names>A. D.</given-names></name><name><surname>Cooley</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Induction of renal fibrotic genes by TGF-<italic>&#x003b2;</italic>1 requires EGFR activation, p53 and reactive oxygen species</article-title><source><italic>Cellular Signalling</italic></source><year>2013</year><volume>25</volume><issue>11</issue><fpage>2198</fpage><lpage>2209</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2013.07.007</pub-id><pub-id pub-id-type="other">2-s2.0-84882727355</pub-id><?supplied-pmid 23872073?><pub-id pub-id-type="pmid">23872073</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overstreet</surname><given-names>J. M.</given-names></name><name><surname>Samarakoon</surname><given-names>R.</given-names></name><name><surname>Meldrum</surname><given-names>K. K.</given-names></name><name><surname>Higgins</surname><given-names>P. J.</given-names></name></person-group><article-title>Redox control of p53 in the transcriptional regulation of TGF-<italic>&#x003b2;</italic>1 target genes through SMAD cooperativity</article-title><source><italic>Cellular Signalling</italic></source><year>2014</year><volume>26</volume><issue>7</issue><fpage>1427</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2014.02.017</pub-id><pub-id pub-id-type="other">2-s2.0-84897444974</pub-id><?supplied-pmid 24613410?><pub-id pub-id-type="pmid">24613410</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordenonsi</surname><given-names>M.</given-names></name><name><surname>Dupont</surname><given-names>S.</given-names></name><name><surname>Maretto</surname><given-names>S.</given-names></name><name><surname>Insinga</surname><given-names>A.</given-names></name><name><surname>Imbriano</surname><given-names>C.</given-names></name><name><surname>Piccolo</surname><given-names>S.</given-names></name></person-group><article-title>Links between tumor suppressors: p53 is required for TGF-<italic>&#x003b2;</italic> gene responses by cooperating with Smads</article-title><source><italic>Cell</italic></source><year>2003</year><volume>113</volume><issue>3</issue><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00308-8</pub-id><pub-id pub-id-type="other">2-s2.0-0038274163</pub-id><?supplied-pmid 12732139?><pub-id pub-id-type="pmid">12732139</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddick</surname><given-names>D. S.</given-names></name><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Bhathena</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Transcriptional suppression of cytochrome P<sub>450</sub> genes by endogenous and exogenous chemicals</article-title><source><italic>Drug Metabolism and Disposition</italic></source><year>2004</year><volume>32</volume><issue>4</issue><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1124/dmd.32.4.367</pub-id><pub-id pub-id-type="other">2-s2.0-12144288241</pub-id><?supplied-pmid 15039287?><pub-id pub-id-type="pmid">15039287</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>G.</given-names></name><name><surname>Wong</surname><given-names>C. C.</given-names></name><name><surname>Cheng</surname><given-names>K. W.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Constantinides</surname><given-names>P. P.</given-names></name><name><surname>Rigas</surname><given-names>B.</given-names></name></person-group><article-title>Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety</article-title><source><italic>British Journal of Pharmacology</italic></source><year>2012</year><volume>167</volume><issue>1</issue><fpage>222</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.01982.x</pub-id><pub-id pub-id-type="other">2-s2.0-84864713877</pub-id><?supplied-pmid 22489789?><pub-id pub-id-type="pmid">22489789</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>R. E.</given-names></name><name><surname>Salama</surname><given-names>A. A. S.</given-names></name><name><surname>Abdel-Rahman</surname><given-names>R. F.</given-names></name><name><surname>Ogaly</surname><given-names>H. A.</given-names></name></person-group><article-title>Hepato-and neuro-protective influences of biopropolis on thioacetamide-induced acute hepatic encephalopathy in rats</article-title><source><italic>Canadian Journal of Physiology and Pharmacology</italic></source><year>2016</year><volume>95</volume><issue>5</issue><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1139/cjpp-2016-0433</pub-id><pub-id pub-id-type="other">2-s2.0-85021093711</pub-id><?supplied-pmid 28177688?><pub-id pub-id-type="pmid">28177688</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eltablawy</surname><given-names>N. A.</given-names></name><name><surname>Ogaly</surname><given-names>H. A.</given-names></name></person-group><article-title>Responsiveness of p53 expression and genetic mutation to CCl<sub>4</sub>-induced DNA damage in rat&#x02019;s liver</article-title><source><italic>International Journal of Genomics and Proteomics</italic></source><year>2014</year><volume>5</volume><issue>1</issue><fpage>99</fpage><lpage>105</lpage></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Antioxidant volatile constituents found in <italic>Mentha piperita</italic> essential oil.</p></caption><graphic xlink:href="OMCL2018-4039753.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Histopathological examination of the liver tissues (H&#x00026;E, &#x000d7;200). (a) Group 1 (normal control) showing normal histological picture of the liver. (b) Group 2 (fibrosis control) showing fatty degeneration of the hepatocytes, hepatocellular necrosis, and mononuclear inflammatory cells aggregation along the collagenous septa. (c) Group 3 (MPEO-treated) showing moderate hepatocellular necrosis, marked reduction of collagenous septa formation and mononuclear inflammatory cells aggregation. (d) Group 4 (MPEO control) showing normal hepatic cellular architecture.</p></caption><graphic xlink:href="OMCL2018-4039753.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Photomicrograph of liver stained with MT stain (&#x000d7;100). (a and d) The normal control (group 1) and MPEO control (group 4) showing normal distribution of collagen fibers in the portal areas. (b) Group 2 (fibrosis control) showing marked fibrous bridging with excessive collagen fibers deposition. (c) Group 3 (MPEO-treated) showing marked attenuation of collagen fibers distribution and deposition. (e) Bar chart represents the hepatic fibrosis expressed as fibrosis %. Mean values with different superscripts are significantly different (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="OMCL2018-4039753.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Representative <italic>&#x003b1;</italic>-SMA immunohistochemistry in liver tissues of the different experimental groups (&#x000d7;200). (a and d) The normal control (group 1) and MPEO control (group 4) showing <italic>&#x003b1;</italic>-SMA staining in the smooth muscle cells of the hepatic vessels. (b) Liver fibrosis control (group 2) showing strong immunostaining reaction in myofibroblast cells. (c) MPEO-treated (group 3) showing marked reduction in immunopositive reactive areas. (e) Bar chart represents the <italic>&#x003b1;</italic>-SMA immunohistochemistry expressed as area %. Mean values with different superscripts are significantly different (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="OMCL2018-4039753.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Representative desmin immunohistochemistry in liver tissues of the different experimental groups (&#x000d7;200). (a and d) The normal control (group 1) and MPEO control (group 4) showing very weak immunopositive reaction. (b) Liver fibrosis control (group 2) showing strong immunostaining reaction in perisinusoidal cells. (c) MPEO-treated (group 3) showing weak immunostaining of perisinusoidal cells. (e) Bar chart represents desmin immunohistochemistry expressed as area %. Mean values with different superscripts are significantly different (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="OMCL2018-4039753.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Representive TGF-<italic>&#x003b2;</italic>1 immunohistochemistry in liver tissue of the different experimental groups (&#x000d7;200). (a and d) The normal control (group 1) and MPEO control (group 4) showing weak immunopositive reaction in portal areas. (b) Liver fibrosis control (group 2) showing intense immunostaining in periductal cells in the portal tract, in perisinusoidal cells, around the blood vessels, and in sinusoidal lining cells. (c) MPEO-treated (group 3) showing mild reaction in some perisinusoidal cells. (e) Bar chart represents the TGF-<italic>&#x003b2;</italic>1 immunohistochemistry in liver expressed as area %. Mean values with different superscripts are significantly different (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="OMCL2018-4039753.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Representive SMAD3 immunohistochemistry in liver tissues of the different experimental groups. (a and e) The normal control and MPEO control (&#x000d7;200). (b) Liver fibrosis control (group 2) showing intense immunostaining reaction (&#x000d7;100). (c) Liver fibrosis control (group 2) showing strong cytoplasmic and nuclear staining (&#x000d7;200). (d) MPEO-treated (group 3) showing marked reduction of immunostaining reaction (&#x000d7;200). (f) Bar chart represents SMAD3 immunohistochemistry expressed as area %. Mean values with different superscripts are significantly different (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="OMCL2018-4039753.007"/></fig><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Quantitative real-time PCR of Tp53 and CYP2E1 mRNA in liver tissues of the different experimental groups. Values are expressed as means&#x02009;&#x000b1;&#x02009;SD. GAPDH was used as an invariant housekeeping control gene for calculating the fold changes (RQ) in mRNA levels. Mean values having different letters are significantly different (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="OMCL2018-4039753.008"/></fig><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Representive p53 immunohistochemistry in liver tissues of the different experimental groups (&#x000d7;400). (a and d) The normal control and MPEO control very weak immunopositive reaction. (b) Liver fibrosis control (group 2) showing intense immunostaining in most of the hepatic cells. (c) MPEO-treated (group 3) showing immunopositive reaction in some hepatic cells. (e) Bar chart represents the p53 immunohistochemistry in liver tissues expressed as area %. Mean values with different superscripts are significantly different (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="OMCL2018-4039753.009"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Primers sequences.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="center" colspan="2" rowspan="1">Primer sequence</th><th align="center" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">GAPDH</td><td align="center" rowspan="1" colspan="1">Forward</td><td align="center" rowspan="1" colspan="1">5&#x02032;-ACCACAGTCCATGCCATCAC-3&#x02032;</td><td align="center" rowspan="2" colspan="1">[<xref rid="B81" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Reverse</td><td align="center" rowspan="1" colspan="1">5&#x02032;-TCCACCACCCTGTTGCTGTA-3&#x02032;</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">TP53</td><td align="center" rowspan="1" colspan="1">Forward</td><td align="center" rowspan="1" colspan="1">5&#x02032;-TCCCTAAGTATCCTCAGTGA-3&#x02032;</td><td align="center" rowspan="2" colspan="1">[<xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Reverse</td><td align="center" rowspan="1" colspan="1">5&#x02032;-GTAATCGAAGCGTTTGTTGA-3&#x02032;</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">CYP2E1</td><td align="center" rowspan="1" colspan="1">Forward</td><td align="center" rowspan="1" colspan="1">5&#x02032;-TCCAGGTTTGCACCAGACTCT-3&#x02032;</td><td align="center" rowspan="2" colspan="1">[<xref rid="B14" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Reverse</td><td align="center" rowspan="1" colspan="1">5&#x02032;-TCCACCACCCTGTTGCTGTA-3&#x02032;</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Chemical composition of MPEO by GC/MS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Retention time</th><th align="center" rowspan="1" colspan="1">Compound</th><th align="center" rowspan="1" colspan="1">Relative %</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">4.8</td><td align="center" rowspan="1" colspan="1">Limonene</td><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">1,8-Cineol</td><td align="center" rowspan="1" colspan="1">1.35</td></tr><tr><td align="left" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1">
<italic>p</italic>-Menthone</td><td align="center" rowspan="1" colspan="1">18.30</td></tr><tr><td align="left" rowspan="1" colspan="1">7.6</td><td align="center" rowspan="1" colspan="1">Beta pinene</td><td align="center" rowspan="1" colspan="1">1.10</td></tr><tr><td align="left" rowspan="1" colspan="1">8.2</td><td align="center" rowspan="1" colspan="1">
<italic>iso</italic>-Menthone</td><td align="center" rowspan="1" colspan="1">5.31</td></tr><tr><td align="left" rowspan="1" colspan="1">8.4</td><td align="center" rowspan="1" colspan="1">Menthol</td><td align="center" rowspan="1" colspan="1">46.70</td></tr><tr><td align="left" rowspan="1" colspan="1">8.9</td><td align="center" rowspan="1" colspan="1">Pulegone</td><td align="center" rowspan="1" colspan="1">6.30</td></tr><tr><td align="left" rowspan="1" colspan="1">8.92</td><td align="center" rowspan="1" colspan="1">
<sc>d</sc>-Camphor</td><td align="center" rowspan="1" colspan="1">3.30</td></tr><tr><td align="left" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">
<sc>l</sc>-Carvone</td><td align="center" rowspan="1" colspan="1">15.20</td></tr><tr><td align="left" rowspan="1" colspan="1">12.8</td><td align="center" rowspan="1" colspan="1">
<italic>trans</italic>-Caryophyllene</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">99.35</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Effects of MPEO on liver enzymes, NO content, and lipid peroxidation byproduct (MDA) in CCl<sub>4</sub>-induced liver fibrosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Experimental groups</th><th align="center" rowspan="1" colspan="1">ALT (U/L)</th><th align="center" rowspan="1" colspan="1">AST (U/L)</th><th align="center" rowspan="1" colspan="1">MDA (<italic>&#x003bc;</italic>M/g tissue)</th><th align="center" rowspan="1" colspan="1">NO (mmol/L)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group 1</td><td align="center" rowspan="1" colspan="1">18.4&#x02009;&#x000b1;&#x02009;0.84</td><td align="center" rowspan="1" colspan="1">46&#x02009;&#x000b1;&#x02009;1.52</td><td align="center" rowspan="1" colspan="1">60.8&#x02009;&#x000b1;&#x02009;2.47</td><td align="center" rowspan="1" colspan="1">3.98&#x02009;&#x000b1;&#x02009;0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Group 2</td><td align="center" rowspan="1" colspan="1">1147.2&#x02009;&#x000b1;&#x02009;42.25</td><td align="center" rowspan="1" colspan="1">1088&#x02009;&#x000b1;&#x02009;65.73</td><td align="center" rowspan="1" colspan="1">143.8&#x02009;&#x000b1;&#x02009;3.97</td><td align="center" rowspan="1" colspan="1">16.21&#x02009;&#x000b1;&#x02009;0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Group 3</td><td align="center" rowspan="1" colspan="1">882&#x02009;&#x000b1;&#x02009;83.19</td><td align="center" rowspan="1" colspan="1">657&#x02009;&#x000b1;&#x02009;31.74</td><td align="center" rowspan="1" colspan="1">89.14&#x02009;&#x000b1;&#x02009;3.16</td><td align="center" rowspan="1" colspan="1">7.11&#x02009;&#x000b1;&#x02009;0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Group 4</td><td align="center" rowspan="1" colspan="1">34&#x02009;&#x000b1;&#x02009;1.12</td><td align="center" rowspan="1" colspan="1">69&#x02009;&#x000b1;&#x02009;1.47</td><td align="center" rowspan="1" colspan="1">71.32&#x02009;&#x000b1;&#x02009;2.36</td><td align="center" rowspan="1" colspan="1">5.42&#x02009;&#x000b1;&#x02009;0.68</td></tr></tbody></table><table-wrap-foot><fn><p>Group 1: normal control; group 2: liver fibrosis control; group 3: MPEO-treated; group 4: MPEO control. Values are expressed as mean&#x02009;&#x000b1;&#x02009;SE. Different superscripts mean significant differences between groups in the same column at <italic>p</italic> &#x0003c; 0.05. ALT: alanine transaminase; AST: aspartate transaminase; NO: nitric oxide; MDA: malondialdehyde.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Effects of MPEO on the hepatic antioxidant profile in CCl<sub>4</sub>-induced liver fibrosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Experimental groups</th><th align="center" rowspan="1" colspan="1">GSH (<italic>&#x003bc;</italic>M/g liver)</th><th align="center" rowspan="1" colspan="1">SOD (U/mg protein)</th><th align="center" rowspan="1" colspan="1">CAT (U/mg protein)</th><th align="center" rowspan="1" colspan="1">TAC (<italic>&#x003bc;</italic>mol/g liver)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group 1</td><td align="center" rowspan="1" colspan="1">12.48&#x02009;&#x000b1;&#x02009;0.32<sup>a</sup></td><td align="center" rowspan="1" colspan="1">82.95&#x02009;&#x000b1;&#x02009;2.56<sup>a</sup></td><td align="center" rowspan="1" colspan="1">2.15&#x02009;&#x000b1;&#x02009;0.07<sup>a</sup></td><td align="center" rowspan="1" colspan="1">5.24&#x02009;&#x000b1;&#x02009;0.25<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Group 2</td><td align="center" rowspan="1" colspan="1">2.93&#x02009;&#x000b1;&#x02009;0.14<sup>b</sup></td><td align="center" rowspan="1" colspan="1">20.29&#x02009;&#x000b1;&#x02009;1.13<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.93&#x02009;&#x000b1;&#x02009;0.06<sup>b</sup></td><td align="center" rowspan="1" colspan="1">2.08&#x02009;&#x000b1;&#x02009;0.16<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Group 3</td><td align="center" rowspan="1" colspan="1">4.8&#x02009;&#x000b1;&#x02009;0.19<sup>c</sup></td><td align="center" rowspan="1" colspan="1">47.6&#x02009;&#x000b1;&#x02009;1.22<sup>c</sup></td><td align="center" rowspan="1" colspan="1">1.37&#x02009;&#x000b1;&#x02009;0.05<sup>c</sup></td><td align="center" rowspan="1" colspan="1">3.88&#x02009;&#x000b1;&#x02009;0.12<sup>c</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Group 4</td><td align="center" rowspan="1" colspan="1">11.6&#x02009;&#x000b1;&#x02009;0.31<sup>a</sup></td><td align="center" rowspan="1" colspan="1">72.45&#x02009;&#x000b1;&#x02009;2.10<sup>a</sup></td><td align="center" rowspan="1" colspan="1">1.94&#x02009;&#x000b1;&#x02009;0.04<sup>a</sup></td><td align="center" rowspan="1" colspan="1">4.30&#x02009;&#x000b1;&#x02009;0.22<sup>a</sup></td></tr></tbody></table><table-wrap-foot><fn><p>Group 1: normal control; group 2: liver fibrosis control; group 3: MPEO-treated; group 4: MPEO control. Values are expressed as mean&#x02009;&#x000b1;&#x02009;SE. Different superscripts mean significant differences between groups in the same column at <italic>p</italic> &#x0003c; 0.05. GSH: reduced glutathione; SOD: superoxide dismutase; CAT: catalase; TAC: total antioxidant capacity.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Effect of MPEO on the pathological grading of CCl<sub>4</sub>-induced fibrotic liver in rats.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">
<italic>n</italic>
</th><th align="center" colspan="7" rowspan="1">Pathological grading of hepatic fibrosis</th><th align="center" rowspan="2" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">0</th><th align="center" rowspan="1" colspan="1">I</th><th align="center" rowspan="1" colspan="1">II</th><th align="center" rowspan="1" colspan="1">III</th><th align="center" rowspan="1" colspan="1">IV</th><th align="center" rowspan="1" colspan="1">V</th><th align="center" rowspan="1" colspan="1">VI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group 1</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Group 2</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.00<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Group 3</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.011<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Group 4</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table><table-wrap-foot><fn><p>Group 1: normal control; group 2: liver fibrosis control; group 3: MPEO-treated; group 4: MPEO control. Data are presented as the mean of ten fields. <italic>n</italic>: number of rats. <sup>a</sup>Significant difference from the control group at <italic>p</italic> &#x0003c; 0.01. <sup>b</sup>Significant difference from model group at <italic>p</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article>